{"title_page": "COVID-19 testing", "text_new": "{{pp-protected|small=yes}}\n{{short description|Diagnostic testing for SARS-CoV-2 virus infection}}\n{{Use Commonwealth English|date=March 2020}}\n{{Use dmy dates|date=April 2020}}\n{{2019\u201320 coronavirus pandemic sidebar|expanded=medical}}\n\n[[File:CDC 2019-nCoV Laboratory Test Kit.jpg|alt=CDC 2019-nCoV Laboratory Test Kit.jpg|thumb|upright=1.3|The US CDC's COVID\u201119 laboratory test kit]]\n'''COVID-19 testing''' can identify the [[SARS-CoV-2]] virus and includes methods that detect the presence of virus itself ([[RT-PCR]] and [[Variants of PCR#Isothermal amplification methods|isothermal nucleic acid amplification]]) and those that detect [[antibodies]] produced in response to infection. Detection of antibodies ([[serology]]) can be used both for diagnosis and population surveillance. Antibody tests show how many people have had the disease, including those whose symptoms were minor or who were asymptomatic. An accurate [[mortality rate]] of the disease and the level of [[herd immunity]] in the population can be determined from the results of this test. However, the duration and effectiveness of this immune response are still unclear.<ref name=JAMA_anibody>{{cite journal |url=https://jamanetwork.com/journals/jama/fullarticle/2764954 |title= The Promise and Peril of Antibody Testing for COVID-19 |publisher=JAMA Network |access-date=April 20, 2020|date = April 17, 2020|doi= 10.1001/jama.2020.6170 |last1= Abbasi |first1= Jennifer |journal= JAMA |pmid= 32301958 }}</ref>\n\nDue to limited testing, as of March 2020 no countries had reliable data on the prevalence of the virus in their population.<ref>{{cite news|title=A fiasco in the making? As the coronavirus pandemic takes hold, we are making decisions without reliable data|date=17 March 2020|author=Ioannidis, John P.A.|url=https://www.statnews.com/2020/03/17/a-fiasco-in-the-making-as-the-coronavirus-pandemic-takes-hold-we-are-making-decisions-without-reliable-data/|publisher=STAT|accessdate=22 March 2020}}</ref> As of {{Testing for Coronavirus disease 2019|shortdate}}, the countries that published their testing data have on average performed a number of tests equal to only {{Testing for Coronavirus disease 2019|avgtested}}% of their population, and no country has tested samples equal to more than {{Testing for Coronavirus disease 2019|maxtested}}% of its population.<ref>{{Cite web|url=https://ourworldindata.org/grapher/full-list-cumulative-total-tests-per-thousand|title=Total tests for COVID-19 per 1,000 people|website=Our World in Data|access-date=16 April 2020}}</ref> There are variations in how much testing has been done across countries.<ref>{{cite web |url=https://www.usatoday.com/story/news/world/2020/04/10/coronavirus-covid-19-small-nations-iceland-big-data/2959797001/ |title= Iceland has tested more of its population for coronavirus than anywhere else. Here's what it learned |publisher= USA Today|access-date=April 16, 2020|date = April 11, 2020}}</ref> This variability is also likely to be affecting reported [[case fatality rate]]s, which have probably been overestimated in many countries, due to [[sampling bias]].<ref name=\":1\">Ward, D. (April 2020) [https://www.researchgate.net/publication/340539075_Sampling_Bias_Explaining_Wide_Variations_in_COVID-19_Case_Fatality_Rates \"Sampling Bias: Explaining Wide Variations in COVID-19 Case Fatality Rates\"]. WardEnvironment.</ref><ref>{{Cite web|url=https://www.bbc.com/future/article/20200401-coronavirus-why-death-and-mortality-rates-differ|title=Coronavirus: Why death and mortality rates differ|last=Henriques|first=Martha|website=bbc.com|language=en|access-date=2020-04-08}}</ref><ref>{{cite web |url=https://www.medrxiv.org/content/10.1101/2020.04.02.20050633v2.full.pdf |doi=10.1101/2020.04.02.20050633 |title= Explaining national differences in the mortality of Covid-19: Individual patient simulation model to investigate the effects of testing policy and other factors on apparent mortality |year= 2020 |last1= Michaels |first1= Jonathan A. |last2= Stevenson |first2= Matt D.}}</ref>\n\n==Test methods==\n===RT-PCR===\nUsing real-time [[reverse transcription polymerase chain reaction]] (rRT-PCR)<ref name=\"20200130cdc\">{{cite web |url=https://www.cdc.gov/coronavirus/2019-ncov/summary.html |title=2019 Novel Coronavirus (2019-nCoV) Situation Summary |date=30 January 2020 |website=[[Centers for Disease Control and Prevention]] |url-status=live |archive-url=https://web.archive.org/web/20200126210549/https://www.cdc.gov/coronavirus/2019-nCoV/summary.html |archive-date=26 January 2020 |access-date=30 January 2020}}</ref> the test can be done on respiratory samples obtained by various methods, including a [[nasopharyngeal swab]] or [[sputum]] sample.<ref name=\"20200129cdc\">{{cite web |url=https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-detection-instructions.html |title=Real-Time RT-PCR Panel for Detection 2019-nCoV |date=29 January 2020 |website=[[Centers for Disease Control and Prevention]] |access-date=1 February 2020 |archive-url=https://web.archive.org/web/20200130202031/https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-detection-instructions.html |archive-date=30 January 2020 |url-status=live }}</ref> Results are generally available within a few hours to 2 days.<ref name=\"globenewswire1977226\">{{cite web |url=https://www.globenewswire.com/news-release/2020/01/30/1977226/0/en/Curetis-Group-Company-Ares-Genetics-and-BGI-Group-Collaborate-to-Offer-Next-Generation-Sequencing-and-PCR-based-Coronavirus-2019-nCoV-Testing-in-Europe.html |title=Curetis Group Company Ares Genetics and BGI Group Collaborate to Offer Next-Generation Sequencing and PCR-based Coronavirus (2019-nCoV) Testing in Europe |date=30 January 2020 |website=GlobeNewswire News Room |access-date=1 February 2020 |archive-url=https://web.archive.org/web/20200131201626/https://www.globenewswire.com/news-release/2020/01/30/1977226/0/en/Curetis-Group-Company-Ares-Genetics-and-BGI-Group-Collaborate-to-Offer-Next-Generation-Sequencing-and-PCR-based-Coronavirus-2019-nCoV-Testing-in-Europe.html |archive-date=31 January 2020 |url-status=live }}</ref> The RT-PCR test performed with throat swabs is only reliable in the first week of the disease. Later on the virus can disappear in the throat while it continues to multiply in the lungs. For infected people tested in the second week, alternatively sample material can then be taken from the deep airways by suction catheter or coughed up material (sputum) can be used.<ref name=\"chrdrosten20200326\">{{cite web |last=Drosten|first=Christian|url=https://www.ndr.de/nachrichten/info/coronaskript146.pdf |title=Coronavirus-Update Folge 22 |date=26 March 2020 |website=NDR |access-date=2 April 2020 |archive-url=https://web.archive.org/web/20200331101408/https://www.ndr.de/nachrichten/info/coronaskript146.pdf |archive-date=31 March 2020 |url-status=live }}</ref>\n<gallery class=\"center\" widths=\"200px\" heights=\"200px\" >\nFile:Infektionsschutzzentrum im Rautenstrauch-Joest-Museum, K\u00f6ln-6313 (cropped).jpg|Demonstration of a [[nasopharyngeal swab]] for COVID\u201119 testing\nFile:Infektionsschutzzentrum im Rautenstrauch-Joest-Museum, K\u00f6ln-6306 (cropped).jpg|Demonstration of a [[throat swab]] for COVID\u201119 testing\nFile:Cycler offen.JPG|A PCR machine\n</gallery>\n\n===Isothermal amplification assays===\nOn 27 March 2020, the FDA approved an \"automated assay\" from Abbott Diagnostics that uses an [[isothermal]] nucleic acid amplification method.<ref name=\"Letter from FDA\">{{cite web |url=https://www.fda.gov/media/136522/download |publisher=FDA |title= Letter from FDA|access-date=April 2, 2020|date = March 27, 2020}}</ref>\n\n===Serology===\n{{multiple image\n | total_width = 300\n | image1 = Antibody tester.jpg\n | alt1 = Machine used to analyze blood samples\n | image2 = Corona antibody test.jpg\n | alt2 = Table showing amounts of IgG and IgM antibodies detected in sample\n | footer = Left: [[Automated analyzer]] for [[immunoassays]], used, for example, to find SARS-CoV-2 antibodies. Right: Example of [[wikt:quantitative|quantitative]] results for SARS-CoV-2 antibody test.}}\n[[File:IgGIgM-Covid19-Test.jpg|thumb|upright=0.5|Point-of-care [[rapid diagnostic test]] for COVID-19]]\nMost [[serology test]]s are in the research stage of development.<ref name=CHS2020/> As of 15 April, four tests had been approved for diagnosis in the United States, all under [[FDA]] [[Emergency Use Authorization]] (EUA).<ref name=CHS2020/><ref>{{cite web |title=Coronavirus (COVID-19) Update: Serological Tests |publisher=U.S. Food and Drug Administration |date=April 7, 2020 |url=https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-serological-tests |accessdate=2020-04-09 }}</ref> The tests are by Chembio Diagnostic System, Ortho Clinical Diagnostics, Mount Sinai Laboratory and Cellex. All four tests must be performed in a laboratory.<ref name=cellex_eua/><ref>{{cite web |url=https://www.fda.gov/media/136966/download |title=Ortho Emergency Use Authorization|publisher= FDA |access-date=April 15, 2020|date =April 14, 2020 }}</ref><ref>{{cite web |url= https://www.fda.gov/media/136965/download|title=Chembio Emergency Use Authorization|publisher= FDA|access-date=April 15, 2020|date =April 14, 2020}}</ref><ref name=MtSinai_EUA>{{cite web |url=https://www.fda.gov/media/137032/download |title= Mount Sinai Emergency Use Authorization|publisher= FDA|access-date=April 18, 2020|date = April 15, 2020}}</ref> The tests by Cellex and Chembio are [[rapid diagnostic test]]s (RDT) that take 10\u201330 minutes to give results. The tests by Ortho and Mount Sinai are enzyme linked immunosorbent assay ([[ELISA]]) tests that takes 1\u20135 hours to give results.<ref name=CHS2020/> In China, the Cellex test had a [[Sensitivity and specificity|specificity]] of 95.6% and a [[Sensitivity and specificity|sensitivity]] of 93.8%.<ref name=CHS2020>{{cite web |url=http://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology-based-tests-for-COVID-19.html |title= Serology-based tests for COVID-19 |publisher=Johns Hopkins |access-date=April 10, 2020}}</ref> Other tests have been approved in other countries.<ref name=CHS2020/>\n\nA number of countries are beginning large scale surveys of their populations using these tests.<ref>{{cite web |title=NIH Begins Study to Quantify Undetected Cases of Coronavirus Infection {{!}} NIH: National Institute of Allergy and Infectious Diseases |url=https://www.niaid.nih.gov/news-events/nih-begins-study-quantify-undetected-cases-coronavirus-infection |website=niaid.nih.gov |accessdate=11 April 2020}}</ref><ref>{{cite news |last1=Mandavilli |first1=Apoorva |last2=Thomas |first2=Katie |title=Will an Antibody Test Allow Us to Go Back to School or Work? |url=https://www.nytimes.com/2020/04/10/health/coronavirus-antibody-test.html |accessdate=11 April 2020 |work=The New York Times |date=10 April 2020}}</ref> A study in California conducted antibody testing in one county and estimated that the number of coronaviruses cases was between 2.5 and 4.2% of the population, or 50 to 85 times higher than the number of confirmed cases.<ref>{{cite journal |url=https://www.medrxiv.org/content/10.1101/2020.03.24.20043067v1 |title= Estimation of SARS-CoV-2 Infection Prevalence in Santa Clara County|publisher=medrxiv.org |access-date=April 17, 2020|date =March 27, 2020 |doi= 10.1101/2020.03.24.20043067|last1= Yadlowsky|first1= Steve|last2= Shah|first2= Nigam|last3= Steinhardt|first3= Jacob|journal=Medrxiv}}</ref><ref>{{cite web |url=https://www.nature.com/articles/d41586-020-01095-0 |title= Antibody tests suggest that coronavirus infections vastly exceed official counts |publisher=Nature |access-date=April 20, 2020|date = April 19, 2020}}</ref>\n\nPart of the immune response to infection is the production of [[antibodies]] including [[IgM]] and [[IgG]]. According to the FDA, IgM antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although levels over the course of infection are not well characterized.<ref name=cellex_eua>{{cite web |url= https://www.fda.gov/media/136622/download |title=Cellex Emergency Use Authorization |publisher= FDA|access-date=April 10, 2020|date = April 1, 2020}}</ref> IgG antibodies to SARS-CoV-2 generally become detectable 10\u201314 days after infection although they may be detected earlier, and normally peak around 28 days after the onset of infection.<ref>{{cite web |url=https://www.nytimes.com/2020/04/10/health/coronavirus-antibody-test.html |title= Will an Antibody Test Allow Us to Go Back to School or Work? |work=New York Times |access-date=April 15, 2020|date =April 10, 2020 }}</ref><ref name=MtSinai_EUA/>  Antibody tests can be used to determine the percentage of the population that has contracted the disease and that is therefore immune. However, it is still not clear how broad and how long and how effective this immune response is.<ref name=JAMA_anibody/><ref name=SA_immun/> It is presumed that once a person has been infected his or her chance of getting a second infection two to three months later is low, but how long that protective immunity will last is not known.<ref name=Nature_antibody>{{cite web |url=https://www.nature.com/articles/d41586-020-01115-z |title= Will antibody tests for the coronavirus really change everything? |publisher=Nature |access-date=April 20, 2020|date = April 18, 2020}}</ref> A study of 175 people in China who had recovered from COVID\u201119 and had mild symptoms reported that 10 individuals produced no detectable protective antibodies.<ref name=Nature_antibody/>\n\nAssays can be performed in central laboratories (CLT) or by [[point-of-care testing]] (PoCT). The high-throughput automated systems in many clinical laboratories will be able to perform these assays but their availability will depend on the rate of production for each system. For CLT a single specimen of peripheral blood is commonly used, although serial specimens can be used to follow the immune response. For PoCT a single specimen of blood is usually obtained by skin puncture. Unlike PCR methods an extraction step is not needed before assay.{{citation needed|date=March 2020}}\n\nIn late March 2020, a number of companies received European approvals for their test kits. The testing capacity is several hundred samples within hours. The antibodies are usually detectable 14 days after the onset of the infection.<ref>Fellmann F. (March 2020). (in German) [https://www.tagesanzeiger.ch/jetzt-beginnt-die-suche-nach-den-genesenen-805626443803 \"Jetzt beginnt die Suche nach den Genesenen\"]. ''Tages Anzeiger''. Retrieved 28 March 2020.</ref>\n\nIn early April, the UK found none of the antibody test kits it purchased were sufficiently good to use.<ref>{{cite news |last1=Chris Smyth |last2=Dominic Kennedy |last3=Billy Kenber |title=Britain has millions of coronavirus antibody tests, but they don't work |url=https://www.thetimes.co.uk/article/britain-has-millions-of-coronavirus-antibody-tests-but-they-don-t-work-j7kb55g89 |accessdate=6 April 2020 |work=[[The Times]] |date=6 April 2020 |language=en |quote=None of the antibody tests ordered by the government is good enough to use, the new testing chief has admitted.  Professor John Newton said that tests ordered from China}}</ref>\n\n===Medical imaging===\nChest CT scans are not recommended for routine screening. Radiologic findings in COVID19 are not specific.<ref>{{Cite web|url=https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection|title=ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection|last=|first=|date=22 March 2020|website=American College of Radiology|url-status=live|archive-url=|archive-date=|access-date=}}</ref><ref name=\":0\" /> Typical features on CT initially include bilateral multilobar [[ground glass opacity|ground-glass opacities]] with a peripheral, asymmetric and posterior distribution.<ref name=\":0\">{{Cite journal|last=Salehi|first=Sana|last2=Abedi|first2=Aidin|last3=Balakrishnan|first3=Sudheer|last4=Gholamrezanezhad|first4=Ali|date=14 March 2020|title=Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients|journal=American Journal of Roentgenology|language=en|pages=1\u20137|doi=10.2214/AJR.20.23034|pmid=32174129|issn=0361-803X|doi-access=free}}</ref> [[Pleural cavity|Subpleural dominance]], [[crazy paving (medicine)|crazy paving]], and [[Pulmonary consolidation|consolidation]] may develop as the disease evolves.<ref name=\":0\" /><ref>{{cite journal |last1=Lee |first1=Elaine Y. P. |last2=Ng |first2=Ming-Yen |last3=Khong |first3=Pek-Lan |title=COVID-19 pneumonia: what has CT taught us? |journal=The Lancet Infectious Diseases |date=24 February 2020 |volume=0 |issue=4 |pages=384\u2013385 |doi=10.1016/S1473-3099(20)30134-1 |pmid=32105641 |pmc=7128449 |url=https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30134-1/fulltext |accessdate=13 March 2020 |language=English |issn=1473-3099}}</ref>\n\n<gallery class=center widths=\"320px\" heights=\"200px\" >\nFile:COVID19CT2.webp|Typical CT imaging findings\nFile:COVID19CT1.webp|CT imaging of rapid progression stage.\n</gallery>\n\n== Approaches to testing ==\n[[File:Covid-testing kiosk.jpg|thumb|A sample collection kiosk for COVID\u201119 testing in India]]\n[[File:Full-list-cumulative-total-tests-per-million.svg|thumb|Timeline of Number of tests per million people in different countries.<ref>{{Cite journal|url=https://ourworldindata.org/coronavirus|title=Coronavirus Disease (COVID-19) \u2013 Statistics and Research|first1=Max|last1=Roser|first2=Hannah|last2=Ritchie|first3=Esteban|last3=Ortiz-Ospina|date=4 March 2020|journal=Our World in Data|via=ourworldindata.org}}</ref>]]\n\nThe United States was testing 100,000 people per day by March 27.<ref>{{Cite web|url=https://ourworldindata.org/grapher/full-list-covid-19-tests-per-day|title=COVID-19: Tests per day|website=Our World in Data|access-date=2020-04-15}}</ref> In comparison, several European countries have been conducting more daily tests per capita than the United States.<ref>{{Cite web|url=https://ourworldindata.org/grapher/full-list-daily-covid-19-tests-per-thousand|title=Daily COVID-19 tests per thousand people|website=Our World in Data|access-date=2020-04-15}}</ref><ref>{{Cite web|url=https://ourworldindata.org/grapher/full-list-cumulative-total-tests-per-thousand|title=Total tests for COVID-19 per 1,000 people|website=Our World in Data|access-date=2020-04-15}}</ref> Three European countries are aiming to conduct 100,000 tests per day \u2013 Germany by mid-April, the United Kingdom by the end of April and France by the end of June. Germany has a large medical diagnostics industry, with over 100 testing labs that provided the technology and infrastructure to enable rapid increases in testing. The UK sought to diversify its life sciences companies into diagnostics to scale up testing capacity.<ref name=\":2\">{{Cite web|url=https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/878121/coronavirus-covid-19-testing-strategy.pdf|title=Coronavirus (COVID-19): Scaling up our testing programmes|last=|first=|date=4 April 2020|website=|publisher=Department of Health and Social Care|url-status=live|archive-url=|archive-date=|access-date=}}</ref>\n\nIn Germany, the [[National Association of Statutory Health Insurance Physicians]] said on 2 March, that it had a capacity for about 12,000 tests per day in the ambulatory setting and 10,700 had been tested in the prior week. Costs are borne by the health insurance when the test is ordered by a physician.<ref name=\"spiegel\">{{Cite news|author1=Nina Weber|url=https://www.spiegel.de/wissenschaft/medizin/coronavirus-und-covid-19-so-testet-deutschland-a-cbb87c09-1804-45df-bb2b-8895e4da91e2|title=Coronavirus und Covid-19: So testet Deutschland|date=5 March 2020|work=Der Spiegel|access-date=23 March 2020|author2=Katherine Rydlink|language=de|author3=Irene Berres}}</ref> According to the president of the [[Robert Koch Institute]], Germany has an overall capacity for 160,000 tests per week.<ref>{{Cite news|last=Oltermann|first=Philip|url=https://www.theguardian.com/world/2020/mar/22/germany-low-coronavirus-mortality-rate-puzzles-experts|title=Germany's low coronavirus mortality rate intrigues experts|date=22 March 2020|work=The Guardian|access-date=24 March 2020|language=en-GB|issn=0261-3077}}</ref> As of 19 March drive-in tests were offered in several large cities.<ref>{{Cite news|url=https://www.deutschlandfunk.de/covid-19-tests-auf-das-coronavirus-wann-wo-und-wie.1939.de.html?drn:news_id=1112050|title=Covid-19 \u2013 Tests auf das Coronavirus: Wann, wo und wie?|date=19 March 2020|work=Deutschlandfunk|access-date=24 March 2020|language=de-DE}}</ref>\nAs of 26 March, the total number of tests performed in Germany was unknown, because only positive results are reported. Health minister [[Jens Spahn]] estimated 200,000 tests per week.<ref name=\"sz\">{{Cite news|last=Charisius|first=Hanno|url=https://www.sueddeutsche.de/gesundheit/covid-19-coronavirus-testverfahren-1.4855487|title=Covid-19: Wie gut testet Deutschland?|date=26 March 2020|access-date=26 March 2020|language=de}}</ref> A first lab survey revealed that as of the end of March a total of at least 483,295 samples were tested and 33,491 samples (6.9%) tested positive for SARS-CoV-2.<ref name=\"rki26\" />\n\nBy the start of April, the United Kingdom was delivering around 10,000 swab tests per day. It set a target for 100,000 per day by the end of April, eventually rising to 250,000 tests per day.<ref name=\":2\" /> The British [[NHS]] has announced that it is piloting a scheme to test suspected cases at home, which removes the risk of a patient infecting others if they come to a hospital or having to disinfect an ambulance if one is used.<ref>{{cite web |title=NHS pilots home testing for coronavirus |url=https://www.mobihealthnews.com/news/europe/nhs-pilots-home-testing-coronavirus |website=MobiHealthNews |archiveurl=https://web.archive.org/web/20200225083044/https://www.mobihealthnews.com/news/europe/nhs-pilots-home-testing-coronavirus|archivedate=25 February 2020|url-status=live |date=24 February 2020}}</ref>\n\nIn [[drive-through]] testing for COVID\u201119 for suspected cases, a healthcare professional takes sample using appropriate precautions.<ref>{{cite web|url=https://www.postbulletin.com/life/health/mayo-clinic-starts-drive-thru-testing-for-covid/article_0087a856-63e3-11ea-be76-c7558f932526.html |title=Mayo Clinic starts drive-thru testing for COVID-19|last=jkiger@postbulletin.com |first=Jeff Kiger|website=PostBulletin.com|language=en|access-date=13 March 2020}}</ref><ref>{{cite web|url=https://www.theverge.com/2020/3/11/21174880/coronavirus-testing-drive-thru-colorado-connecticut-washington |title=Some states are offering drive-thru coronavirus testing|last=Hawkins|first=Andrew J.|date=11 March 2020|website=The Verge|language=en|access-date=13 March 2020}}</ref> Drive-through centers have helped [[South Korea]] do some of the fastest, most-extensive testing of any country.<ref>{{cite web|url=https://www.npr.org/sections/goatsandsoda/2020/03/13/815441078/south-koreas-drive-through-testing-for-coronavirus-is-fast-and-free?t=1584350615980 |title=South Korea's Drive-Through Testing For Coronavirus Is Fast \u2013 And Free|date=11 March 2020|website=npr |language=en|access-date=16 March 2020}}</ref> Hong Kong has set up a scheme where suspected patients can stay home, \"[the] emergency department will give a specimen tube to the patient\", they spit into it, send it back and get a test result a while after.<ref>{{cite web|url=https://www.npr.org/sections/goatsandsoda/2020/02/23/808290390/in-age-of-covid-19-hong-kong-innovates-to-test-and-quarantine-thousands|title=In Age of COVID-19, Hong Kong Innovates To Test And Quarantine Thousands|website=NPR.org|language=en}}</ref>\n\nIn Israel, researchers at [[Technion \u2013 Israel Institute of Technology|Technion]] and [[Rambam Health Care Campus|Rambam Hospital]] developed and tested a method for testing samples from 64 patients simultaneously, by [[group testing|pooling the samples]] and only testing further if the combined sample is found to be positive.<ref>{{cite news |title=Pooling method allows dozens of COVID-19 tests to run simultaneously |url=https://medicalxpress.com/news/2020-03-pooling-method-dozens-covid-simultaneously.html |accessdate=24 March 2020 |work=medicalxpress.com |language=en-us}}</ref><ref>{{cite news |title=Israeli team has coronavirus test kit to test dozens of people at once |url=https://www.jpost.com/HEALTH-SCIENCE/Acceleration-in-multiple-coronavirus-tests-at-once-by-Israel-research-team-621533 |accessdate=24 March 2020 |work=The Jerusalem Post {{!}} JPost.com}}</ref><ref>{{cite news |last1=Staff |first1=Israel21c |title=Israelis introduce method for accelerated COVID-19 testing |url=https://www.israel21c.org/israelis-introduce-method-for-accelerated-covid-19-testing/ |accessdate=24 March 2020 |work=Israel21c |date=19 March 2020}}</ref> Pool testing was then adopted in Israel, Germany, South Korea,<ref>{{cite news |title=[Coronavirus] Verified 'sample pooling' introduced to prevent herd infection in S. Korea |url=http://www.ajudaily.com/view/20200409140926759 |accessdate=19 April 2020 |work=www.ajudaily.com |date=9 April 2020 |language=en}}</ref> and [[Nebraska]],<ref>{{cite news |title=Gov. Ricketts provides update on coronavirus testing |url=https://www.3newsnow.com/news/coronavirus/live-gov-ricketts-provides-coronavirus-briefing-3-24-20 |accessdate=19 April 2020 |work=KMTV |date=24 March 2020 |language=en}}</ref> and the Indian states [[Uttar Pradesh]],<ref>{{cite news |title=Latest coronavirus update: UP to begin 'pool testing' of Covid suspects |url=https://www.freepressjournal.in/india/latest-coronavirus-update-up-to-begin-pool-testing-of-covid-suspects |accessdate=19 April 2020 |work=Free Press Journal |language=en}}</ref> [[West Bengal]],<ref>{{cite news |author=Sumati Yengkhom |title=West Bengal to start pool testing of samples in low-risk zones |url=https://timesofindia.indiatimes.com/city/kolkata/bengal-to-start-pool-testing-of-samples-in-low-risk-zones/articleshow/75227413.cms |accessdate=19 April 2020 |work=The Times of India |language=en}}</ref> [[Punjab]],<ref>{{cite news |title=Punjab launches pool testing |url=https://www.tribuneindia.com/news/punjab/punjab-launches-pool-testing-71594 |accessdate=19 April 2020}}</ref> [[Chhattisgarh]],<ref>{{cite news |title='Chhattisgarh to adopt pool sample testing': Health minister TS Singh Deo on Covid-19 |url=https://www.hindustantimes.com/india-news/chhattisgarh-to-adopt-pool-sample-testing-health-minister-ts-singh-deo-on-covid-19/story-qUnbTE2WgfhAv72aqclkXN.html |accessdate=19 April 2020 |work=Hindustan Times |date=15 April 2020 |language=en}}</ref> and [[Maharashtra]].<ref>{{cite news |title=Maharashtra to go for pool testing to defeat coronavirus |url=https://www.deccanherald.com/national/west/maharashtra-to-go-for-pool-testing-to-defeat-coronavirus-824331.html |accessdate=19 April 2020 |work=Deccan Herald |date=12 April 2020 |language=en}}</ref>\n\nIn Wuhan a makeshift 2000-sq-meter emergency detection laboratory named \"Huo-Yan\" ({{Zh|c=\u706b\u773c|s=|t=|p=}}, \"Fire Eye\") was opened on 5 February 2020 by [[BGI Group|BGI]],<ref name=\":19\">{{Cite web|url=https://www.bloomberg.com/news/articles/2020-02-04/china-will-soon-find-out-if-mass-quarantine-worked-virus-update |title=Wuhan Test Lab Opens; CDC Ships Diagnostic Kits: Virus Update|last=|first= |date=5 February 2020|website=Bloomberg |url-status=live|archive-url=|archive-date= |access-date=7 February 2020}}</ref><ref name=\":23\">{{Cite web|url=https://www.afp.com/en/news/826/china-virus-crisis-deepens-whistleblower-doctor-dies-doc-1oq8cx13 |title=China virus crisis deepens as whistleblower doctor dies|website=AFP.com|date=27 February 2012|language=en|access-date=7 February 2020}}</ref> which can process over 10,000 samples a day.<ref>{{cite news|url=http://news.sciencenet.cn/htmlnews/2020/2/435435.shtm |script-title=zh:\u65e5\u68c0\u6d4b\u91cf\u8fbe\u4e07\u4efd\u7684\"\u706b\u773c\"\u5b9e\u9a8c\u5ba4\u8fde\u591c\u8bd5\u8fd0\u884c}}</ref><ref name=\":23\" /> With the construction overseen by BGI-founder [[Wang Jian (geneticist)|Wang Jian]] and taking 5-days,<ref>{{Cite web|url=https://www.genengnews.com/insights/bgis-coronavirus-response-build-a-lab-in-wuhan-in-a-week/ |title=BGI's Coronavirus Response? Build a Lab in Wuhan|date=12 February 2020|website=GEN \u2013 Genetic Engineering and Biotechnology News|language=en-US|access-date=27 March 2020}}</ref> modelling has show cases in Hubei would have been 47% higher and the corresponding cost of the tackling the quarantine would have doubled if this testing capacity had not come into operation.{{citation needed|date=April 2020}} The Wuhan Laboratory has been promptly followed by Huo-Yan labs in [[Shenzhen]], [[Tianjin]], [[Beijing]], and [[Shanghai]], in a total of 12 cities across China. By 4 March 2020 the daily throughput totals were 50,000 tests per day.<ref>{{Cite web|url=https://www.bgi.com/global/covid-19-local-laboratory-solution/ |title=COVID-19 Local Laboratory Solution|website=BGI \u2013 Global|language=en-GB|access-date=27 March 2020}}</ref>\n\nOpen source, multiplexed designs released by Origami Assays have been released that can test as many as 1122 patient samples for COVID19 using only 93 assays.<ref>{{cite web |url= https://www.smarterbetter.design/origamiassays/default/index |title= Origami Assays  |publisher= Origami Assays |access-date=April 7, 2020|date =April 2, 2020 }}</ref>  These balanced designs can be run in small laboratories without the need for robotic liquid handlers.\n\nBy March, [[Shortages related to the 2019\u201320 coronavirus pandemic|shortages]] and insufficient amounts of [[reagent]] has become a [[Bottleneck (production)|bottleneck]] for mass testing in the EU and UK<ref>{{cite web |title=Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK \u2013seventh update |url=https://www.ecdc.europa.eu/sites/default/files/documents/RRA-seventh-update-Outbreak-of-coronavirus-disease-COVID-19.pdf |publisher=[[European Centre for Disease Prevention and Control]] |accessdate=29 March 2020 |pages=15\u201316 |date=25 March 2020 |quote=the current shortages of laboratory consumables and reagents affect diagnostic capacity and hamper the epidemic response at the national and local levels. The laboratories have experienced delayed or missing deliveries of swabbing material, plastic consumables, RNA extraction and RT-PCR reagents, and PPE. This is affecting laboratories in all EU/EEA countries. |url-status=live}}</ref> and the US.<ref>{{cite web |last1=Baird |first1=Robert P. |title=Why Widespread Coronavirus Testing Isn't Coming Anytime Soon |url=https://www.newyorker.com/news/news-desk/why-widespread-coronavirus-testing-isnt-coming-anytime-soon |website=[[The New Yorker]] |accessdate=29 March 2020 |archiveurl= https://web.archive.org/web/20200328133105/https://www.newyorker.com/news/news-desk/why-widespread-coronavirus-testing-isnt-coming-anytime-soon |archivedate=28 March 2020 |language=en |date=24 March 2020 |quote=South Dakota, said that her state\u2019s public-health laboratory\u2014the only lab doing COVID-19 testing in the state\u2014had so much trouble securing reagents that it was forced to temporarily stop testing altogether. also noted critical shortages of extraction kits, reagents, and test kits |url-status=live}}</ref><ref>{{cite web |last1=Ossola |first1=Alexandra |title=Here are the coronavirus testing materials that are in short supply in the US |url=https://qz.com/1822596/all-the-coronavirus-test-materials-in-short-supply-in-the-us/ |website=Quartz |accessdate=29 March 2020 |archiveurl= https://web.archive.org/web/20200326174135/https://qz.com/1822596/all-the-coronavirus-test-materials-in-short-supply-in-the-us/ |archivedate=26 March 2020 |language=en |date=25 March 2020 |quote=extract the virus\u2019s genetic material\u2014in this case, RNA\u2014using a set of chemicals that usually come in pre-assembled kits. \u201cThe big shortage is extraction kits\u201d There are no easy replacements here: \u201cThese reagents that are used in extraction are fairly complex chemicals. They have to be very pure, and they have to be in pure solution\u201d |url-status=live}}</ref> This has led some authors to explore sample preparation protocols that involve heating samples at {{cvt|98|C|F}} for 5 minutes to release [[RNA genome]]s for further testing.<ref name=ssi-boil>{{cite web |last1=Fomsgaard |first1=Anders |title=Statens Serum Institut (SSI) solves essential COVID-19 testing deficiency problem |url=https://en.ssi.dk/news/news/2020/03-ssi--solves-essential-covid19-testing-deficiency-problem |website=en.ssi.dk |publisher=[[Statens Serum Institut]] |archiveurl= https://web.archive.org/web/20200329085152/https://en.ssi.dk/news/news/2020/03-ssi--solves-essential-covid19-testing-deficiency-problem |archivedate=29 March 2020 |language=en |date=27 March 2020 |url-status=live |quote=several countries are in lack of the chemical reagents necessary to test their citizens for the disease. }}</ref><ref>{{cite web |title=Danish researchers behind simple&nbsp;coronavirus test method |publisher=[[The Copenhagen Post]] |url=http://cphpost.dk/?p=112522 |website=cphpost.dk |archiveurl=https://web.archive.org/web/20200328130357/http://cphpost.dk/?p=112522 |archivedate=28 March 2020 |date=28 March 2020 |url-status=live}}</ref>\n\nOn 31 March it was announced [[United Arab Emirates]] was now testing more of its population for Coronavirus per head than any other country, and was on track to scale up the level of testing to reach the bulk of the population.<ref>{{Cite news|last=Sullivan (now|first=Helen|url=https://www.theguardian.com/world/live/2020/mar/31/coronavirus-live-news-usa-confirmed-cases-double-china-update-uk-italy-spain-europe-latest-updates?page=with%3Ablock-5e8377658f087564da1e3396|title=Global confirmed virus death toll passes 40,000 \u2013 as it happened|date=31 March 2020|work=The Guardian|access-date=1 April 2020|last2=Rawlinson|first2=earlier); Kevin|language=en-GB|issn=0261-3077|last3=Gayle|first3=Damien|last4=Topping|first4=Alexandra|last5=Mohdin|first5=and Aamna|last6=Willsher|first6=Kim|last7=Wintour|first7=Patrick|last8=Wearden|first8=Graeme|last9=Greenfield|first9=Patrick}}</ref> This was through a combination of drive-through capability, and purchasing a population-scale mass-throughput laboratory from Group 42 and [[BGI Group|BGI]] (based on their \"Huo-Yan\" emergency detection laboratories in China). Constructed in 14 days, the lab is capable of conducting tens of thousands RT-PCR tests per day and is the first in the world of this scale to be operational outside of China.<ref>{{Cite web|url=https://www.gulftoday.ae/news/2020/03/31/uae-sets-up-covid-19-detection-lab-in-just-14-days|title=VIDEO: UAE sets up COVID-19 detection lab in just 14 days|last=|first=|date=31 March 2020|website=Gulf Today|url-status=live|archive-url=|archive-date=|access-date=}}</ref>\n\nOn 8 April 2020, In India, the Supreme Court of India ruled that private labs should be reimbursed at the appropriate time for COVID-19 tests <ref> [http://www.businessworld.in/article/Private-Labs-Should-Be-Reimbursed-At-Appropriate-Time-For-COVID-19-Tests-Says-AIIMS-RDA-General-Secretary/13-04-2020-188994/ Private Labs Should Be Reimbursed At Appropriate Time For COVID-19 Tests, Says AIIMS RDA General Secretary] </ref> However private labs have stated that they are unable to scale up the testing because of the price cap put on the testing and labs being forced to make advance payment to suppliers while they receive deferred payment from hospitals. <ref> [https://economictimes.indiatimes.com/news/politics-and-nation/private-laboratories-struggle-with-price-caps-on-covid-19-tests-do-only-17-tests/articleshow/75310421.cms Covid-19: Private laboratories struggle with price caps, do only 17% tests] </ref>\n\n==Production and volume==\n[[File:Lab-specimens-tested.jpg|thumb|upright=1.6|Number of tests done per day in the United States.<br />\nBlue: CDC lab<br />\nOrange: Public health lab<br />\nGray: Data incomplete due to reporting lag<br />\nNot shown: Testing at private labs; total exceeded 100,000 per day by March 27<ref>{{Cite web|url=https://arstechnica.com/tech-policy/2020/04/americas-covid-19-testing-has-stalled-and-thats-a-big-problem/|title=America's COVID-19 testing has stalled, and that's a big problem|first=Timothy B.|last=Lee|date=2 April 2020|website=Ars Technica}}</ref>]]\n\nDifferent testing recipes targeting different parts of the coronavirus genetic profile were developed in China, France, Germany, Hong Kong, Japan, the United Kingdom, and the United States. The [[World Health Organization]] adopted the German recipe for manufacturing kits sent to low-income countries without the resources to develop their own. The German recipe was published on 17 January 2020; the protocol developed by the [[United States Centers for Disease Control]] (CDC) was not available until 28 January, delaying available tests in the U.S.<ref>{{Cite web|url=https://www.politifact.com/factchecks/2020/mar/16/joe-biden/biden-falsely-says-trump-administration-rejected-w/|title=PolitiFact \u2013 Biden falsely says Trump administration rejected WHO coronavirus test kits (that were never offered)|website=@politifact}}</ref>\n\nChina<ref name=Wuhan-virus /> and the United States<ref name=Boston-virus /> had problems with the reliability of test kits early in the outbreak, and these countries and Australia<ref>{{cite web|url=https://www.theguardian.com/australia-news/2020/mar/14/coronavirus-australian-stocks-of-covid-19-testing-kits-rapidly-deteriorating-says-chief-medical-officer|title=Australian stocks of coronavirus testing kits 'rapidly deteriorating', says chief medical officer|first=Melissa|last=Davey|date=14 March 2020|via=www.theguardian.com}}</ref> were unable to supply enough kits to satisfy demand and recommendations for testing by health experts. In contrast, experts say South Korea's broad availability of testing helped reduce the spread of the novel coronavirus. Testing capacity, largely in private sector labs, was built up over several years by the South Korean government.<ref>{{cite web|url=https://www.npr.org/2020/03/12/815097813/experts-credit-south-koreas-extensive-testing-for-curbing-coronavirus-spread|title=Experts Credit South Korea's Extensive Testing For Curbing Coronavirus Spread|website=NPR.org}}</ref> On 16 March, the [[World Health Organization]] called for ramping up the testing programmes as the best way to slow the advance of COVID\u201119 pandemic.<ref>{{cite news |title='Test, Test, Test': WHO Chief's Coronavirus Message to World |url=https://www.nytimes.com/reuters/2020/03/16/world/europe/16reuters-healthcare-coronavirus-who.html |accessdate=16 March 2020 |work=The New York Times |date=16 March 2020}}</ref><ref>{{cite news |last1=Reuters |first1=Source |title='Test, test, test': WHO calls for more coronavirus testing \u2013 video |url=https://www.theguardian.com/world/video/2020/mar/16/test-test-test-who-calls-for-more-coronavirus-testing-video |accessdate=16 March 2020 |work=The Guardian |date=16 March 2020}}</ref>\n\nHigh demand for testing due to wide spread of the virus caused backlogs of hundreds of thousands of tests at private U.S. labs, and supplies of swabs and chemical reagents became strained.<ref>{{Cite web|url=https://www.npr.org/sections/health-shots/2020/04/03/826564948/coronavirus-testing-backlogs-continue-as-laboratories-struggle-to-keep-up-with-d|title=Coronavirus Testing Backlogs Continue As Laboratories Struggle To Keep Up With Demand|website=NPR.org}}</ref>\n\n==Available tests==\n===PCR based===\nWhen scientists from China first released information on the COVID\u201119 viral genome on January 11, 2020, the Malaysian Institute for Medical Research (IMR) successfully produced the \u201cprimers and probes\u201d specific to SARS-CoV-2 on the very same day. The IMR's laboratory in [[Kuala Lumpur]] had initiated early preparedness by setting up reagents to detect coronavirus using the rt-PCR method.<ref>{{Cite web|url=https://kpkesihatan.com/2020/02/13/laboratory-readiness-for-detecting-the-2019-novel-coronavirus-2019-ncov-infection-in-malaysia/|title=Laboratory Readiness for Detecting the 2019 novel coronavirus (2019-nCoV) infection in Malaysia|last=|first=|date=9 February 2020|website=Director-General of Health, Malaysia|url-status=live|archive-url=|archive-date=|access-date=}}</ref> The WHO reagent sequence (primers and probes) released several days later was very similar to that produced in the IMR's laboratory, which was used to  diagnose Malaysia's first COVID\u201119 patient on January 24, 2020.<ref>{{Cite web|url=https://www.thestar.com.my/opinion/letters/2020/03/26/malaysia-must-ramp-up-testing?itm_source=parsely-api|title=Malaysia must ramp up testing|last=|first=|date=26 March 2020|website=The Star Malaysia|url-status=live|archive-url=|archive-date=|access-date=}}</ref>\n\n[[Public Health England]] developed a test by 10 January,<ref>{{Cite news|last=|first=|url=https://uk.reuters.com/article/uk-health-coronavirus-britain-modelling-idUKKCN21R2UF|title=UK defends coronavirus response after Reuters investigation|date=2020-04-09|work=Reuters|access-date=2020-04-12|url-status=live|language=en|quote=After developing a test for the new virus by Jan. 10}}</ref> using real-time RT-PCR (RdRp gene) assay based on oral swabs.<ref>{{Cite web|url=https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/guidance-and-sop-covid-19-virus-testing-in-nhs-laboratories-v1.pdf|title=COVID-19 virus testing in NHS laboratories|last=|first=|date=16 March 2020|website=|publisher=NHS England and NHS Improvement|url-status=live|archive-url=|archive-date=|access-date=}}</ref> The test detected the presence of any type of coronavirus including specifically identifying SARS-CoV-2. It was rolled out to twelve laboratories across the United Kingdom on February 10.<ref>{{Cite web|url=https://www.gov.uk/government/news/phe-novel-coronavirus-diagnostic-test-rolled-out-across-uk|title=PHE novel coronavirus diagnostic test rolled out across UK|website=GOV.UK|language=en|access-date=30 March 2020|postscript=none}}; {{Cite news|url=https://www.bbc.com/news/uk-51221915|title='Increased likelihood' of China virus reaching UK|date=23 January 2020|work=BBC News|access-date=30 March 2020|language=en-GB|postscript=none}}; {{Cite web|url=https://www.pharmaceutical-journal.com/news-and-analysis/news/phe-tells-patients-with-suspected-coronavirus-to-call-gp-or-nhs-111/20207619.article|title=PHE tells patients with suspected coronavirus to call GP or NHS 111|date=27 January 2020|publisher=The Pharmaceutical Journal|language=en|access-date=30 March 2020}}</ref> Another early PCR test was developed by [[Charit\u00e9]] in Berlin, working with academic collaborators in Europe and Hong Kong, and published on 23 January. It used rtRT-PCR, and formed the basis of 250,000 kits for distribution by the [[World Health Organization]] (WHO).<ref name=sheridan>{{cite journal |last1=Sheridan |first1=Cormac |title=Coronavirus and the race to distribute reliable diagnostics |url=https://www.nature.com/articles/d41587-020-00002-2 |journal=Nature Biotechnology |language=en |doi=10.1038/d41587-020-00002-2 |date=19 February 2020|volume=38 |issue=4 |pages=382\u2013384 |pmid=32265548 |doi-access=free }}</ref> The South Korean company Kogenebiotech developed a clinical grade, PCR-based SARS-CoV-2 detection kit (''PowerChek Coronavirus'') on 28 January 2020.<ref>{{cite web|url=http://www.kogene.co.kr/eng/index.php |title=KogeneBiotech |publisher=Kogene.co.kr |date= |accessdate=16 March 2020}}</ref><ref>{{cite news |last1=Jeong |first1=Sei-im |title=Korea approves 2 more COVID-19 detection kits for urgent use \u2013 Korea Biomedical Review |url=http://www.koreabiomed.com/news/articleView.html?idxno=7561 |accessdate=12 March 2020 |work=koreabiomed.com |date=28 February 2020 |language=ko}}</ref> It looks for the \"E\" gene shared by all [[beta coronavirus]]es, and the RdRp gene specific to SARS-CoV-2.<ref>{{Cite web|url=http://www.kogene.co.kr/eng/about_us/news/listbody.php?h_gcode=board&h_code=7&po_no=288|title=ABOUT US &#124; NEWS|website=kogene.co.kr}}</ref>\n\nIn China, [[BGI Group]] was one of the first companies to receive emergency use approval from China's [[National Medical Products Administration]] for a PCR-based SARS-CoV-2 detection kit.<ref>{{cite web|url=https://www.genomeweb.com/regulatory-news-fda-approvals/bgi-sequencer-coronavirus-molecular-assays-granted-emergency-use|title=BGI Sequencer, Coronavirus Molecular Assays Granted Emergency Use Approval in China|website=GenomeWeb|access-date=9 March 2020}}</ref>\n\nIn the United States, the CDC distributed its SARS-CoV-2 Real Time PCR Diagnostic Panel to public health labs through the International Reagent Resource.<ref>{{cite web|url=https://www.internationalreagentresource.org/|title=International Reagent Resource |website=internationalreagentresource.org}}</ref> One of three genetic tests in older versions of the test kits caused inconclusive results due to faulty reagents, and a bottleneck of testing at the CDC in Atlanta; this resulted in an average of fewer than 100 samples a day being successfully processed throughout the whole of February 2020. Tests using two components were not determined to be reliable until 28 February 2020, and it was not until then that state and local laboratories were permitted to begin testing.<ref>[https://www.cdc.gov/media/releases/2020/t0228-COVID-19-update.html Transcript for the CDC Telebriefing Update on COVID-19], 28 February 2020</ref> The test was approved by the FDA under an EUA.{{citation needed|date=March 2020}}\n\nUS commercial labs began testing in early March 2020. As of 5 March 2020 [[LabCorp]] announced nationwide availability of COVID\u201119 testing based on RT-PCR.<ref>{{Cite web|url=https://ir.labcorp.com/news-releases/news-release-details/labcorp-launches-test-coronavirus-disease-2019-covid-19|title=LabCorp Launches Test for Coronavirus Disease 2019 (COVID-19)|website=Laboratory Corporation of America Holdings}}</ref> [[Quest Diagnostics]] similarly made nationwide COVID\u201119 testing available as of 9 March 2020.<ref>{{cite web|url=https://www.questdiagnostics.com/home/Covid-19/|title=Covid19 : COVID-19|website=questdiagnostics.com}}</ref>\n\nIn Russia, the COVID\u201119 test was developed and produced by the [[State Research Center of Virology and Biotechnology VECTOR]]. On 11 February 2020 the test was registered by the [[Federal Service for Surveillance in Healthcare]].<ref>{{Cite web|url=http://www.interfax-russia.ru/kaleidoscope.asp?id=1104973|title=\u0412 \u0420\u043e\u0441\u0441\u0438\u0438 \u0437\u0430\u0440\u0435\u0433\u0438\u0441\u0442\u0440\u0438\u0440\u043e\u0432\u0430\u043d\u0430 \u043e\u0442\u0435\u0447\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u0430\u044f \u0442\u0435\u0441\u0442-\u0441\u0438\u0441\u0442\u0435\u043c\u0430 \u0434\u043b\u044f \u043e\u043f\u0440\u0435\u0434\u0435\u043b\u0435\u043d\u0438\u044f \u043a\u043e\u0440\u043e\u043d\u0430\u0432\u0438\u0440\u0443\u0441\u0430|date=14 February 2020|website=Interfax-Russia.ru}}</ref>\n\nOn 12 March 2020, [[Mayo Clinic]] was reported to have developed a test to detect COVID\u201119 infection.<ref>{{cite web|url=https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-develops-test-to-detect-covid-19-infection/|title=Mayo Clinic develops test to detect COVID-19 infection|last=Plumbo|first=Ginger|website=[[Mayo Clinic]]|language=en-US|access-date=13 March 2020}}</ref>\n\nOn 19 March 2020, the FDA issued EUA to [[Abbott Laboratories]]<ref>{{cite web |url=https://www.molecular.abbott/us/en/products/instrumentation/m2000-realtime-system |title=M2000 Realtime System |publisher= Abbott Labs |access-date=April 13, 2020}}</ref> for a test on Abbott's m2000 system; the FDA had previously issued similar authorization to [[Hologic]],<ref>{{cite web |url=https://investors.hologic.com/press-releases/press-release-details/2020/Hologics-Molecular-Test-for-the-Novel-Coronavirus-SARS-CoV-2-Receives-FDA-Emergency-Use-Authorization/default.aspx |title=Hologic's Molecular Test for the Novel Coronavirus, SARS-CoV-2, Receives FDA Emergency Use Authorization |publisher=Hologic |access-date=April 13, 2020|date = March 16, 2020}}</ref> [[LabCorp]],<ref>{{cite web |url=https://ir.labcorp.com/news-releases/news-release-details/labcorp-launches-test-coronavirus-disease-2019-covid-19 |title= LabCorp Launches Test for Coronavirus Disease 2019 (COVID-19) |publisher=LabCorp |access-date=April 13, 2020}}</ref> and [[Thermo Fisher Scientific]].<ref>{{cite web |url=https://www.thermofisher.com/us/en/home/clinical/clinical-genomics/pathogen-detection-solutions/coronavirus-2019-ncov/genetic-analysis/taqpath-rt-pcr-covid-19-kit.html |title= TaqPath COVID-19 Multiplex Diagnostic Solution |publisher=ThermoFisher |access-date=April 13, 2020}}</ref><ref>{{cite web|url=https://www.ibtimes.com/fda-approves-abbott-laboratories-coronavirus-test-company-ship-150000-kits-2942677 |title=FDA Approves Abbott Laboratories Coronavirus Test, Company To Ship 150,000 Kits |date=19 March 2020 |website=IBTimes.com |archive-url=https://web.archive.org/web/20200320210743/https://www.ibtimes.com/fda-approves-abbott-laboratories-coronavirus-test-company-ship-150000-kits-2942677 |archive-date=20 March 2020 |url-status=live}}</ref> On 21 March 2020, [[Cepheid Inc|Cepheid]] similarly received an EUA from the FDA for a test that takes about 45 minutes on its GeneXpert system; the same system that runs the [[GeneXpert MTB/RIF]].<ref>{{cite web| url=https://www.eastbaytimes.com/2020/03/21/coronavirus-test-45-minute-cepheid-sunnyvale-covid-19-test/ |title=Sunnyvale company wins FDA approval for first rapid coronavirus test with 45-minute detection time |website=EastBayTimes.com |date=21 March 2020 |archive-url=https://archive.is/iz2H7# |archive-date=22 March 2020 |url-status=live}}</ref><ref>{{Cite web|url=https://www.cepheid.com/coronavirus|title=Xpert\u00ae Xpress SARS-CoV-2 has received FDA Emergency Use Authorization|website=www.cepheid.com|language=en-US|access-date=2020-04-13}}</ref>\n\nOn 13 April, [[Health Canada]] approved a test from [[Spartan Bioscience]]. Institutions may \"test patients\" with a handheld [[DNA analyzer]] \"and receive results without having to send samples away to a [central] lab.\"<ref name=\"carly\">{{cite news |title=Health Canada approves new rapid COVID-testing kits |url=https://www.theglobeandmail.com/canada/article-health-canada-approves-new-rapid-covid-testing-kits/ |publisher=The Globe and Mail Inc |date=13 April 2020}}</ref><ref>{{cite web |url=https://www.spartanbio.com/ |title=The power of DNA testing for everyone |publisher=Spartan Bioscience |access-date=April 14, 2020}}</ref>\n\n===Isothermal nucleic amplification===\n[[File:President Trump Delivers Remarks During a Coronavirus Update Briefing (49720569077).jpg|thumb|US President [[Donald Trump]] displays a COVID\u201119 testing kit from [[Abbott Laboratories]] in March 2020]]\nThe FDA has approved a test by [[Abbott Laboratories]] that uses isothermal nucleic acid amplification technology instead of PCR.<ref name=\"Letter from FDA\"/> Since this does not require a series of alternating temperature cycles (like [[PCR]] tests typically do) this method can deliver positive results in as little as five minutes and negative results in 13 minutes.  There are currently about 18,000 of these machines in the U.S. and Abbott expects to ramp up manufacturing to deliver 50,000 tests per day.<ref>{{cite web |url=https://www.usatoday.com/story/news/health/2020/03/28/coronavirus-fda-authorizes-abbott-labs-fast-portable-covid-test/2932766001/ |title='A game changer': FDA authorizes Abbott Labs' portable, 5-minute coronavirus test the size of a toaster |publisher=USA Today |access-date=April 20, 2020|date =March 28, 2020 }}</ref>\n\n===Accuracy===\nIn March 2020 China<ref name=Wuhan-virus>[https://www.bloomberg.com/news/articles/2020-03-12/heartbreak-in-the-streets-of-wuhan Heartbreak in the Streets of Wuhan]</ref> reported problems with accuracy in their test kits.\n\nIn the United States, the test kits developed by the CDC had \"flaws;\" the government then removed the bureaucratic barriers that had prevented private testing.<ref name=Boston-virus>{{cite web|url=https://www.bostonglobe.com/2020/03/14/metro/baker-sets-up-virus-command-center/|title=State figures on testing raise questions about efforts to contain outbreak |website=The BostonGlobe.com |quote=flaws with the testing kits first distributed by the federal government and bureaucratic hurdles that held up testing by private labs at hospitals, universities and testing chains}}</ref>\n\nSpain purchased test kits from Chinese firm  Shenzhen Bioeasy Biotechnology Co Ltd, but found that results were inaccurate. The firm explained that the incorrect results may be a result of a failure to collect samples or use the kits correctly. The Spanish ministry said it will withdraw the kits that returned incorrect results, and would replace them with a different testing kit provided by Shenzhen Bioeasy.<ref>{{Cite web|url=https://www.reuters.com/article/us-health-coronavirus-shenzhen-bioeasy-s-idUSKBN21E161|title=Chinese firm to replace exported coronavirus test kits deemed defective by Spain|date=27 March 2020|via=www.reuters.com}}</ref>\n\n80% of test kits the Czech Republic purchased from China gave wrong results.<ref>{{Cite web|url=https://www.praguemorning.cz/80-of-rapid-covid-19-tests-the-czech-republic-bought-from-china-are-wrong/|title=80% of Rapid COVID-19 Tests the Czech Republic Bought From China are Wrong|first=Prague|last=Morning|date=26 March 2020}}</ref><ref>{{cite news |last1=VOJT\u011aCH BLA\u017dEK |title=\u00da\u0159ad dop\u0159edu psal, kdy mohou rychlotesty selhat. I tak je st\u00e1t nasadil |url=https://www.seznamzpravy.cz/clanek/rychlotesty-neodhali-cerstve-nakazene-pacienty-varoval-zdravotni-ustav-95174 |accessdate=7 April 2020 |work=Zeznam Zpr\u00e1vy |date=23 March 2020 |language=Czech |quote=Indeed, the rapid tests that arrived from China a few days ago do not really reliably detect the infection at an early stage}}</ref>\n\nSlovakia purchased 1.2&nbsp;million test kits from China which were found to be inaccurate. Prime Minister Matovi\u010d suggested these be dumped into the [[Danube]].<ref>{{Cite web|url=https://fortune.com/2020/04/01/europe-china-coronavirus-testing-help-regret/|title=Europe turned to China for coronavirus testing help. Why some are now regretting it|website=Fortune}}</ref>\n\nAte\u015f Kara of the Turkish Health Ministry said the test kits Turkey purchased from China had a \"high error rate\" and did not \"put them into use.\"<ref>{{Cite web|url=https://www.duvarenglish.com/health-2/coronavirus/2020/03/27/coronavirus-test-kits-purchased-from-china-are-unreliable-says-science-committee-member/|title=Coronavirus test kits purchased from China are unreliable, says Science Committee member|website=www.duvarenglish.com}}</ref><ref>{{Cite web|url=http://www.middleeasteye.net/news/coronavirus-turkey-faulty-chinese-kits-not-use|title=Coronavirus: Turkey rejects Chinese testing kits over inaccurate results|website=Middle East Eye}}</ref>\n\nThe UK purchased 3.5&nbsp;million test kits from China but in early April 2020 announced these were not usable.<ref>{{Cite web|url=https://www.thetimes.co.uk/article/britain-has-millions-of-coronavirus-antibody-tests-but-they-don-t-work-j7kb55g89|title=Britain has millions of coronavirus antibody tests, but they don't work|first=Chris Smyth, Whitehall Editor &#124; Dominic Kennedy, Investigations Editor &#124; Billy Kenber, Investigations|last=Reporter|via=www.thetimes.co.uk}}</ref><ref>{{Cite web|url=https://www.independent.co.uk/news/uk/home-news/coronavirus-test-antibody-kit-uk-china-nhs-matt-hancock-a9449816.html|title=Government's testing chief admits none of 3.5m coronavirus antibody kits work sufficiently|date=6 April 2020|website=The Independent}}</ref>\n\nOn April 21, 2020 [[Indian Council of Medical Research]], India has advised states to stop using the rapid antibody test kits purchased from China after receiving complaints from one state. Rajasthan health minister Raghu Sharma on Apr 21, 2020 said the kits gave only 5.4 percent accurate results against the expectation of 90 percent accuracy.<ref>{{Cite web|url=https://www.telegraphindia.com/india/icmr-asks-states-not-to-use-rapid-test-kits-for-two-days/cid/1766876|title=ICMR asks states not to use rapid test kits for two days|date=21 April 2020|website=The Telegraph}}</ref>\n\n===Confirmatory testing===\nWHO recommends that countries that do not have testing capacity and national laboratories with limited experience on COVID\u201119 send their first five positives and the first ten negative COVID\u201119 samples to one of the 16 WHO reference laboratories for confirmatory testing.<ref>{{cite web |title=National laboratories |url=https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance |website=who.int |language=en}}</ref><ref>{{Cite web|url=https://www.gov.uk/government/news/phe-novel-coronavirus-diagnostic-test-rolled-out-across-uk|title=PHE novel coronavirus diagnostic test rolled out across UK|last=|first=|date=|website=GOV.UK|language=en|url-status=live|archive-url=|archive-date=|access-date=2020-04-12|quote=In addition to processing samples from suspected cases in this country, PHE is now working as a reference laboratory for WHO, testing samples from countries that do not have assured testing capabilities.}}</ref> Out of the 16 reference laboratories, 7 are in Asia, 5 in Europe, 2 in Africa, 1 in North America and 1 in Australia.<ref>{{cite web |title=Specimen referral for COVID-19 \u2013 operational details of WHO reference laboratories providing confirmatory testing for COVID-19 |url=https://www.who.int/docs/default-source/coronaviruse/who-reference-laboratories-providing-confirmatory-testing-for-covid-19.pdf?sfvrsn=a03a01e6_2 |website=World Health Organization |accessdate=29 March 2020}}</ref>\n\n===WHO Emergency Use Listing===\n{| class=\"wikitable\" style = \"float: right; margin-left:15px\"\n|+Diagnostic tests accepted by the WHO for procurement\n|-\n! Date listed !! Product name !! Manufacturer\n|-\n| 03/4/2020 || Cobas SARS-CoV-2 qualitative assay for use on the cobas 6800/8800 Systems ||[[Roche Diagnostics|Roche Molecular Systems]]\n|-\n| 07/4/2020 || Coronavirus (COVID-19) genesig rtPCR assay ||[[Primerdesign]]\n|-\n| 09/4/2020 || Abbott Realtime SARS-CoV-2 ||[[Abbott Laboratories|Abbott Molecular]]\n|}\nAs of 7 April 2020, the WHO had accepted two diagnostic tests for procurement under the Emergency Use Listing procedure (EUL) for use during the COVID\u201119 pandemic, in order to increase access to quality-assured, accurate tests for the disease.<ref>{{cite web |title=WHO lists two COVID-19 tests for emergency use |url=https://www.who.int/news-room/detail/07-04-2020-who-lists-two-covid-19-tests-for-emergency-use |website=[[World Health Organization]] |accessdate=10 April 2020}}</ref> Both [[in vitro]] diagnostics, the tests are genesig Real-Time PCR Coronavirus (COVID\u201119) manufactured by [[Primerdesign]], and cobas SARS-CoV-2 Qualitative assay for use on the cobas\u00ae 6800/8800 Systems by [[Roche Diagnostics|Roche Molecular Systems]]. Approval means that these tests can also be supplied by the [[United Nations]] and other procurement agencies supporting the COVID\u201119 response.\n\n==Clinical effectiveness==\nTesting, followed with quarantine of those who tested positive and tracing of those with whom the SARS-CoV-2 positive people had had contact, resulted in positive outcomes.{{clarify|reason=Positive in the sense of epidemic containment being a \"positive\" social goal? Or a greater number of SARS-CoV-2 positive detections?|date=April 2020}}.{{citation needed|date=April 2020}}\n\n===Italy===\nResearchers working in the Italian town of [[V\u00f2]], the site of the first COVID\u201119 death in Italy, conducted two rounds of testing on the entire population of about 3,400 people, about ten days apart. About half the people testing positive had no symptoms, and all discovered cases were quarantined. With travel to the commune restricted, this eliminated new infections completely.<ref>{{Cite web|url=https://nationalpost.com/news/world/how-an-experiment-helped-one-italian-town-find-submerged-infections-cut-new-covid-19-cases-to-zero|title=How an experiment helped one Italian town find 'submerged infections,' cut new COVID-19 cases to zero &#124; National Post|date=19 March 2020}}</ref>\n\n===Singapore===\nWith aggressive contact tracing, inbound travel restrictions, testing, and quarantining, the [[2020 coronavirus pandemic in Singapore]] has proceeded much more slowly than in other developed countries {{Dubious|date=April 2020}}, but without extreme restrictions like forced closure of restaurants and retail establishments.  Many events have been cancelled, and Singapore did start advising residents to stay at home on 28 March, but schools reopened on time after holiday break on 23 March.<ref>{{Cite web|url=https://www.msn.com/en-sg/news/singapore/covid-19-outbreak-petition-to-close-schools-in-singapore-garners-7700-signatures-to-date/ar-BB11C87Z?li=BBr8YXK|title=COVID-19 outbreak: Petition to close schools in Singapore garners 7,700 signatures to date|website=msn.com}}</ref>\n\n===Others===\nSeveral other countries, such as Iceland<ref>{{Cite web|url=https://nordiclifescience.org/covid-19-first-results-of-the-voluntary-screening-in-iceland/|title=COVID-19: First results of the voluntary screening in Iceland|date=2020-03-27|website=Nordic Life Science \u2013 the leading Nordic life science news service|language=en-US|access-date=2020-04-05}}</ref> and South Korea,<ref>{{Cite web|url=https://www.sciencemag.org/news/2020/03/coronavirus-cases-have-dropped-sharply-south-korea-whats-secret-its-success|title=Coronavirus cases have dropped sharply in South Korea. What's the secret to its success?|last=NormileMar. 17|first=Dennis|last2=2020|date=2020-03-17|website=Science {{!}} AAAS|language=en|access-date=2020-04-05|last3=Am|first3=8:00}}</ref> have also managed the pandemic with aggressive contact tracing, inbound travel restrictions, testing, and quarantining, but with less aggressive lock-downs. A statistical study has found that countries that have tested more, relative to the number of deaths, have much lower [[case fatality rate]]s, probably because these countries are better able to detect those with only mild or no symptoms.<ref name=\":1\" />\n\n==Research and development==\nA test which uses [[monoclonal antibody|monoclonal antibodies]] which bind to the [[nucleocapsid protein]] (N protein) of the SARS-CoV-2 is being developed in Taiwan, with the hope that it can provide results in 15 to 20 minutes just like a [[rapid influenza test]].<ref>{{cite news |title=\u4e2d\u592e\u7814\u7a76\u9662\u7db2\u7ad9 |url=https://www.sinica.edu.tw/en/news/6505 |accessdate=12 March 2020 |work=sinica.edu.tw |publisher=Sinca}}</ref> The World Health Organization raised concerns on April 8 that these tests need to be validated for the disease and are in a research stage only.<ref>{{cite web |title=Advice on the use of point-of-care immunodiagnostic tests for COVID-19 |url=https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19 |website=who.int |accessdate=11 April 2020 |language=en}}</ref> The United States [[Food and Drug Administration]] approved an antibody test on April 2,<ref>Romano, Andrew. (7 April 2020). \n \"Fauci once dismissed concerns about 'silent carriers' of coronavirus. Not anymore.\" [https://news.yahoo.com/fauci-once-dismissed-concerns-about-silent-carriers-of-coronavirus-not-anymore-161718057.html Yahoo News] Retrieved 17 April 2020.</ref> but some researchers warn that such tests should not drive public health decisions unless the percentage of COVID\u201119 survivors who are producing neutralizing antibodies is also known.<ref name=SA_immun>McKenna, Stacey. (10 April 2020). \"What Immunity to COVID-19 Really Means\". [https://www.scientificamerican.com/article/what-immunity-to-covid-19-really-means/ Scientific American website] Retrieved 17 April 2020.</ref>\n\n==Virus testing statistics by country==\nThe figures are influenced by the country's testing policy. In countries with similar spread of infection, a country that only tests people admitted to hospitals will have lower \"Positive / million people\" and higher \"% (Percentage of positive tests)\" figures than a country that tests all citizens whether or not they are showing symptoms.<ref>{{cite web |url=https://www.researchgate.net/publication/340539075 |title=Sampling Bias: Explaining Wide Variations in COVID-19 Case Fatality Rates |publisher=ResearchGate |access-date=April 17, 2020|date=April 1, 2020 }}</ref>\n\n{{COVID-19 testing by country|state=expanded}}\n\n==Virus testing statistics by country subdivision==\n{{COVID-19 testing by country subdivision|state=expanded}}\n\n==References==\n{{reflist}}\n\n==External links==\n{{Commons category}}\n* [https://ourworldindata.org/covid-testing ''Data on COVID-19 testing''] at [[Our World in Data]] (March 31, 2020)\n* [https://www.c-span.org/video/?470277-1/federal-health-officials-testify-coronavirus-outbreak-response&start=4478 ''COVID-19 Testing (at least) \u2013 now Free for all?'' (CDC; US Congress; CSPAN video/6:00; March 12, 2020)]\n* [https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.3.2000045 Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR]; [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988269/ NCBI-PMC], [https://dx.doi.org/10.2807%2F1560-7917.ES.2020.25.3.2000045 DOI] (January 23, 2020)\n\n{{2019\u201320 coronavirus pandemic}}\n\n[[Category:Infectious disease blood tests]]\n[[Category:COVID-19|Testing]]\n[[Category:Medical responses to the 2019\u201320 coronavirus pandemic]]\n", "text_old": "{{pp-protected|small=yes}}\n{{short description|Diagnostic testing for SARS-CoV-2 virus infection}}\n{{Use Commonwealth English|date=March 2020}}\n{{Use dmy dates|date=April 2020}}\n{{2019\u201320 coronavirus pandemic sidebar|expanded=medical}}\n\n[[File:CDC 2019-nCoV Laboratory Test Kit.jpg|alt=CDC 2019-nCoV Laboratory Test Kit.jpg|thumb|upright=1.3|The US CDC's COVID\u201119 laboratory test kit]]\n'''COVID-19 testing''' can identify the [[SARS-CoV-2]] virus and includes methods that detect the presence of virus itself ([[RT-PCR]] and [[Variants of PCR#Isothermal amplification methods|isothermal nucleic acid amplification]]) and those that detect [[antibodies]] produced in response to infection. Detection of antibodies ([[serology]]) can be used both for diagnosis and population surveillance. Antibody tests show how many people have had the disease, including those whose symptoms were minor or who were asymptomatic. An accurate [[mortality rate]] of the disease and the level of [[herd immunity]] in the population can be determined from the results of this test. However, the duration and effectiveness of this immune response are still unclear.<ref name=JAMA_anibody>{{cite journal |url=https://jamanetwork.com/journals/jama/fullarticle/2764954 |title= The Promise and Peril of Antibody Testing for COVID-19 |publisher=JAMA Network |access-date=April 20, 2020|date = April 17, 2020|doi= 10.1001/jama.2020.6170 |last1= Abbasi |first1= Jennifer |journal= JAMA |pmid= 32301958 }}</ref>\n\nDue to limited testing, as of March 2020 no countries had reliable data on the prevalence of the virus in their population.<ref>{{cite news|title=A fiasco in the making? As the coronavirus pandemic takes hold, we are making decisions without reliable data|date=17 March 2020|author=Ioannidis, John P.A.|url=https://www.statnews.com/2020/03/17/a-fiasco-in-the-making-as-the-coronavirus-pandemic-takes-hold-we-are-making-decisions-without-reliable-data/|publisher=STAT|accessdate=22 March 2020}}</ref> As of {{Testing for Coronavirus disease 2019|shortdate}}, the countries that published their testing data have on average performed a number of tests equal to only {{Testing for Coronavirus disease 2019|avgtested}}% of their population, and no country has tested samples equal to more than {{Testing for Coronavirus disease 2019|maxtested}}% of its population.<ref>{{Cite web|url=https://ourworldindata.org/grapher/full-list-cumulative-total-tests-per-thousand|title=Total tests for COVID-19 per 1,000 people|website=Our World in Data|access-date=16 April 2020}}</ref> There are variations in how much testing has been done across countries.<ref>{{cite web |url=https://www.usatoday.com/story/news/world/2020/04/10/coronavirus-covid-19-small-nations-iceland-big-data/2959797001/ |title= Iceland has tested more of its population for coronavirus than anywhere else. Here's what it learned |publisher= USA Today|access-date=April 16, 2020|date = April 11, 2020}}</ref> This variability is also likely to be affecting reported [[case fatality rate]]s, which have probably been overestimated in many countries, due to [[sampling bias]].<ref name=\":1\">Ward, D. (April 2020) [https://www.researchgate.net/publication/340539075_Sampling_Bias_Explaining_Wide_Variations_in_COVID-19_Case_Fatality_Rates \"Sampling Bias: Explaining Wide Variations in COVID-19 Case Fatality Rates\"]. WardEnvironment.</ref><ref>{{Cite web|url=https://www.bbc.com/future/article/20200401-coronavirus-why-death-and-mortality-rates-differ|title=Coronavirus: Why death and mortality rates differ|last=Henriques|first=Martha|website=bbc.com|language=en|access-date=2020-04-08}}</ref><ref>{{cite web |url=https://www.medrxiv.org/content/10.1101/2020.04.02.20050633v2.full.pdf |doi=10.1101/2020.04.02.20050633 |title= Explaining national differences in the mortality of Covid-19: Individual patient simulation model to investigate the effects of testing policy and other factors on apparent mortality |year= 2020 |last1= Michaels |first1= Jonathan A. |last2= Stevenson |first2= Matt D.}}</ref>\n\n==Test methods==\n===RT-PCR===\nUsing real-time [[reverse transcription polymerase chain reaction]] (rRT-PCR)<ref name=\"20200130cdc\">{{cite web |url=https://www.cdc.gov/coronavirus/2019-ncov/summary.html |title=2019 Novel Coronavirus (2019-nCoV) Situation Summary |date=30 January 2020 |website=[[Centers for Disease Control and Prevention]] |url-status=live |archive-url=https://web.archive.org/web/20200126210549/https://www.cdc.gov/coronavirus/2019-nCoV/summary.html |archive-date=26 January 2020 |access-date=30 January 2020}}</ref> the test can be done on respiratory samples obtained by various methods, including a [[nasopharyngeal swab]] or [[sputum]] sample.<ref name=\"20200129cdc\">{{cite web |url=https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-detection-instructions.html |title=Real-Time RT-PCR Panel for Detection 2019-nCoV |date=29 January 2020 |website=[[Centers for Disease Control and Prevention]] |access-date=1 February 2020 |archive-url=https://web.archive.org/web/20200130202031/https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-detection-instructions.html |archive-date=30 January 2020 |url-status=live }}</ref> Results are generally available within a few hours to 2 days.<ref name=\"globenewswire1977226\">{{cite web |url=https://www.globenewswire.com/news-release/2020/01/30/1977226/0/en/Curetis-Group-Company-Ares-Genetics-and-BGI-Group-Collaborate-to-Offer-Next-Generation-Sequencing-and-PCR-based-Coronavirus-2019-nCoV-Testing-in-Europe.html |title=Curetis Group Company Ares Genetics and BGI Group Collaborate to Offer Next-Generation Sequencing and PCR-based Coronavirus (2019-nCoV) Testing in Europe |date=30 January 2020 |website=GlobeNewswire News Room |access-date=1 February 2020 |archive-url=https://web.archive.org/web/20200131201626/https://www.globenewswire.com/news-release/2020/01/30/1977226/0/en/Curetis-Group-Company-Ares-Genetics-and-BGI-Group-Collaborate-to-Offer-Next-Generation-Sequencing-and-PCR-based-Coronavirus-2019-nCoV-Testing-in-Europe.html |archive-date=31 January 2020 |url-status=live }}</ref> The RT-PCR test performed with throat swabs is only reliable in the first week of the disease. Later on the virus can disappear in the throat while it continues to multiply in the lungs. For infected people tested in the second week, alternatively sample material can then be taken from the deep airways by suction catheter or coughed up material (sputum) can be used.<ref name=\"chrdrosten20200326\">{{cite web |last=Drosten|first=Christian|url=https://www.ndr.de/nachrichten/info/coronaskript146.pdf |title=Coronavirus-Update Folge 22 |date=26 March 2020 |website=NDR |access-date=2 April 2020 |archive-url=https://web.archive.org/web/20200331101408/https://www.ndr.de/nachrichten/info/coronaskript146.pdf |archive-date=31 March 2020 |url-status=live }}</ref>\n<gallery class=\"center\" widths=\"200px\" heights=\"200px\" >\nFile:Infektionsschutzzentrum im Rautenstrauch-Joest-Museum, K\u00f6ln-6313 (cropped).jpg|Demonstration of a [[nasopharyngeal swab]] for COVID\u201119 testing\nFile:Infektionsschutzzentrum im Rautenstrauch-Joest-Museum, K\u00f6ln-6306 (cropped).jpg|Demonstration of a [[throat swab]] for COVID\u201119 testing\nFile:Cycler offen.JPG|A PCR machine\n</gallery>\n\n===Isothermal amplification assays===\nOn 27 March 2020, the FDA approved an \"automated assay\" from Abbott Diagnostics that uses an [[isothermal]] nucleic acid amplification method.<ref name=\"Letter from FDA\">{{cite web |url=https://www.fda.gov/media/136522/download |publisher=FDA |title= Letter from FDA|access-date=April 2, 2020|date = March 27, 2020}}</ref>\n\n===Serology===\n{{multiple image\n | total_width = 300\n | image1 = Antibody tester.jpg\n | alt1 = Machine used to analyze blood samples\n | image2 = Corona antibody test.jpg\n | alt2 = Table showing amounts of IgG and IgM antibodies detected in sample\n | footer = Left: [[Automated analyzer]] for [[immunoassays]], used, for example, to find SARS-CoV-2 antibodies. Right: Example of [[quantitative]] results for SARS-CoV-2 antibody test.}}\n[[File:IgGIgM-Covid19-Test.jpg|thumb|upright=0.5|Point-of-care [[rapid diagnostic test]] for COVID-19]]\nMost [[serology test]]s are in the research stage of development.<ref name=CHS2020/> As of 15 April, four tests had been approved for diagnosis in the United States, all under [[FDA]] [[Emergency Use Authorization]] (EUA).<ref name=CHS2020/><ref>{{cite web |title=Coronavirus (COVID-19) Update: Serological Tests |publisher=U.S. Food and Drug Administration |date=April 7, 2020 |url=https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-serological-tests |accessdate=2020-04-09 }}</ref> The tests are by Chembio Diagnostic System, Ortho Clinical Diagnostics, Mount Sinai Laboratory and Cellex. All four tests must be performed in a laboratory.<ref name=cellex_eua/><ref>{{cite web |url=https://www.fda.gov/media/136966/download |title=Ortho Emergency Use Authorization|publisher= FDA |access-date=April 15, 2020|date =April 14, 2020 }}</ref><ref>{{cite web |url= https://www.fda.gov/media/136965/download|title=Chembio Emergency Use Authorization|publisher= FDA|access-date=April 15, 2020|date =April 14, 2020}}</ref><ref name=MtSinai_EUA>{{cite web |url=https://www.fda.gov/media/137032/download |title= Mount Sinai Emergency Use Authorization|publisher= FDA|access-date=April 18, 2020|date = April 15, 2020}}</ref> The tests by Cellex and Chembio are [[rapid diagnostic test]]s (RDT) that take 10\u201330 minutes to give results. The tests by Ortho and Mount Sinai are enzyme linked immunosorbent assay ([[ELISA]]) tests that takes 1\u20135 hours to give results.<ref name=CHS2020/> In China, the Cellex test had a [[Sensitivity and specificity|specificity]] of 95.6% and a [[Sensitivity and specificity|sensitivity]] of 93.8%.<ref name=CHS2020>{{cite web |url=http://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology-based-tests-for-COVID-19.html |title= Serology-based tests for COVID-19 |publisher=Johns Hopkins |access-date=April 10, 2020}}</ref> Other tests have been approved in other countries.<ref name=CHS2020/>\n\nA number of countries are beginning large scale surveys of their populations using these tests.<ref>{{cite web |title=NIH Begins Study to Quantify Undetected Cases of Coronavirus Infection {{!}} NIH: National Institute of Allergy and Infectious Diseases |url=https://www.niaid.nih.gov/news-events/nih-begins-study-quantify-undetected-cases-coronavirus-infection |website=niaid.nih.gov |accessdate=11 April 2020}}</ref><ref>{{cite news |last1=Mandavilli |first1=Apoorva |last2=Thomas |first2=Katie |title=Will an Antibody Test Allow Us to Go Back to School or Work? |url=https://www.nytimes.com/2020/04/10/health/coronavirus-antibody-test.html |accessdate=11 April 2020 |work=The New York Times |date=10 April 2020}}</ref> A study in California conducted antibody testing in one county and estimated that the number of coronaviruses cases was between 2.5 and 4.2% of the population, or 50 to 85 times higher than the number of confirmed cases.<ref>{{cite journal |url=https://www.medrxiv.org/content/10.1101/2020.03.24.20043067v1 |title= Estimation of SARS-CoV-2 Infection Prevalence in Santa Clara County|publisher=medrxiv.org |access-date=April 17, 2020|date =March 27, 2020 |doi= 10.1101/2020.03.24.20043067|last1= Yadlowsky|first1= Steve|last2= Shah|first2= Nigam|last3= Steinhardt|first3= Jacob|journal=Medrxiv}}</ref><ref>{{cite web |url=https://www.nature.com/articles/d41586-020-01095-0 |title= Antibody tests suggest that coronavirus infections vastly exceed official counts |publisher=Nature |access-date=April 20, 2020|date = April 19, 2020}}</ref>\n\nPart of the immune response to infection is the production of [[antibodies]] including [[IgM]] and [[IgG]]. According to the FDA, IgM antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although levels over the course of infection are not well characterized.<ref name=cellex_eua>{{cite web |url= https://www.fda.gov/media/136622/download |title=Cellex Emergency Use Authorization |publisher= FDA|access-date=April 10, 2020|date = April 1, 2020}}</ref> IgG antibodies to SARS-CoV-2 generally become detectable 10\u201314 days after infection although they may be detected earlier, and normally peak around 28 days after the onset of infection.<ref>{{cite web |url=https://www.nytimes.com/2020/04/10/health/coronavirus-antibody-test.html |title= Will an Antibody Test Allow Us to Go Back to School or Work? |work=New York Times |access-date=April 15, 2020|date =April 10, 2020 }}</ref><ref name=MtSinai_EUA/>  Antibody tests can be used to determine the percentage of the population that has contracted the disease and that is therefore immune. However, it is still not clear how broad and how long and how effective this immune response is.<ref name=JAMA_anibody/><ref name=SA_immun/> It is presumed that once a person has been infected his or her chance of getting a second infection two to three months later is low, but how long that protective immunity will last is not known.<ref name=Nature_antibody>{{cite web |url=https://www.nature.com/articles/d41586-020-01115-z |title= Will antibody tests for the coronavirus really change everything? |publisher=Nature |access-date=April 20, 2020|date = April 18, 2020}}</ref> A study of 175 people in China who had recovered from COVID\u201119 and had mild symptoms reported that 10 individuals produced no detectable protective antibodies.<ref name=Nature_antibody/>\n\nAssays can be performed in central laboratories (CLT) or by [[point-of-care testing]] (PoCT). The high-throughput automated systems in many clinical laboratories will be able to perform these assays but their availability will depend on the rate of production for each system. For CLT a single specimen of peripheral blood is commonly used, although serial specimens can be used to follow the immune response. For PoCT a single specimen of blood is usually obtained by skin puncture. Unlike PCR methods an extraction step is not needed before assay.{{citation needed|date=March 2020}}\n\nIn late March 2020, a number of companies received European approvals for their test kits. The testing capacity is several hundred samples within hours. The antibodies are usually detectable 14 days after the onset of the infection.<ref>Fellmann F. (March 2020). (in German) [https://www.tagesanzeiger.ch/jetzt-beginnt-die-suche-nach-den-genesenen-805626443803 \"Jetzt beginnt die Suche nach den Genesenen\"]. ''Tages Anzeiger''. Retrieved 28 March 2020.</ref>\n\nIn early April, the UK found none of the antibody test kits it purchased were sufficiently good to use.<ref>{{cite news |last1=Chris Smyth |last2=Dominic Kennedy |last3=Billy Kenber |title=Britain has millions of coronavirus antibody tests, but they don't work |url=https://www.thetimes.co.uk/article/britain-has-millions-of-coronavirus-antibody-tests-but-they-don-t-work-j7kb55g89 |accessdate=6 April 2020 |work=[[The Times]] |date=6 April 2020 |language=en |quote=None of the antibody tests ordered by the government is good enough to use, the new testing chief has admitted.  Professor John Newton said that tests ordered from China}}</ref>\n\n===Medical imaging===\nChest CT scans are not recommended for routine screening. Radiologic findings in COVID19 are not specific.<ref>{{Cite web|url=https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection|title=ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection|last=|first=|date=22 March 2020|website=American College of Radiology|url-status=live|archive-url=|archive-date=|access-date=}}</ref><ref name=\":0\" /> Typical features on CT initially include bilateral multilobar [[ground glass opacity|ground-glass opacities]] with a peripheral, asymmetric and posterior distribution.<ref name=\":0\">{{Cite journal|last=Salehi|first=Sana|last2=Abedi|first2=Aidin|last3=Balakrishnan|first3=Sudheer|last4=Gholamrezanezhad|first4=Ali|date=14 March 2020|title=Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients|journal=American Journal of Roentgenology|language=en|pages=1\u20137|doi=10.2214/AJR.20.23034|pmid=32174129|issn=0361-803X|doi-access=free}}</ref> [[Pleural cavity|Subpleural dominance]], [[crazy paving (medicine)|crazy paving]], and [[Pulmonary consolidation|consolidation]] may develop as the disease evolves.<ref name=\":0\" /><ref>{{cite journal |last1=Lee |first1=Elaine Y. P. |last2=Ng |first2=Ming-Yen |last3=Khong |first3=Pek-Lan |title=COVID-19 pneumonia: what has CT taught us? |journal=The Lancet Infectious Diseases |date=24 February 2020 |volume=0 |issue=4 |pages=384\u2013385 |doi=10.1016/S1473-3099(20)30134-1 |pmid=32105641 |pmc=7128449 |url=https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30134-1/fulltext |accessdate=13 March 2020 |language=English |issn=1473-3099}}</ref>\n\n<gallery class=center widths=\"320px\" heights=\"200px\" >\nFile:COVID19CT2.webp|Typical CT imaging findings\nFile:COVID19CT1.webp|CT imaging of rapid progression stage.\n</gallery>\n\n== Approaches to testing ==\n[[File:Covid-testing kiosk.jpg|thumb|A sample collection kiosk for COVID\u201119 testing in India]]\n[[File:Full-list-cumulative-total-tests-per-million.svg|thumb|Timeline of Number of tests per million people in different countries.<ref>{{Cite journal|url=https://ourworldindata.org/coronavirus|title=Coronavirus Disease (COVID-19) \u2013 Statistics and Research|first1=Max|last1=Roser|first2=Hannah|last2=Ritchie|first3=Esteban|last3=Ortiz-Ospina|date=4 March 2020|journal=Our World in Data|via=ourworldindata.org}}</ref>]]\n\nThe United States was testing 100,000 people per day by March 27.<ref>{{Cite web|url=https://ourworldindata.org/grapher/full-list-covid-19-tests-per-day|title=COVID-19: Tests per day|website=Our World in Data|access-date=2020-04-15}}</ref> In comparison, several European countries have been conducting more daily tests per capita than the United States.<ref>{{Cite web|url=https://ourworldindata.org/grapher/full-list-daily-covid-19-tests-per-thousand|title=Daily COVID-19 tests per thousand people|website=Our World in Data|access-date=2020-04-15}}</ref><ref>{{Cite web|url=https://ourworldindata.org/grapher/full-list-cumulative-total-tests-per-thousand|title=Total tests for COVID-19 per 1,000 people|website=Our World in Data|access-date=2020-04-15}}</ref> Three European countries are aiming to conduct 100,000 tests per day \u2013 Germany by mid-April, the United Kingdom by the end of April and France by the end of June. Germany has a large medical diagnostics industry, with over 100 testing labs that provided the technology and infrastructure to enable rapid increases in testing. The UK sought to diversify its life sciences companies into diagnostics to scale up testing capacity.<ref name=\":2\">{{Cite web|url=https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/878121/coronavirus-covid-19-testing-strategy.pdf|title=Coronavirus (COVID-19): Scaling up our testing programmes|last=|first=|date=4 April 2020|website=|publisher=Department of Health and Social Care|url-status=live|archive-url=|archive-date=|access-date=}}</ref>\n\nIn Germany, the [[National Association of Statutory Health Insurance Physicians]] said on 2 March, that it had a capacity for about 12,000 tests per day in the ambulatory setting and 10,700 had been tested in the prior week. Costs are borne by the health insurance when the test is ordered by a physician.<ref name=\"spiegel\">{{Cite news|author1=Nina Weber|url=https://www.spiegel.de/wissenschaft/medizin/coronavirus-und-covid-19-so-testet-deutschland-a-cbb87c09-1804-45df-bb2b-8895e4da91e2|title=Coronavirus und Covid-19: So testet Deutschland|date=5 March 2020|work=Der Spiegel|access-date=23 March 2020|author2=Katherine Rydlink|language=de|author3=Irene Berres}}</ref> According to the president of the [[Robert Koch Institute]], Germany has an overall capacity for 160,000 tests per week.<ref>{{Cite news|last=Oltermann|first=Philip|url=https://www.theguardian.com/world/2020/mar/22/germany-low-coronavirus-mortality-rate-puzzles-experts|title=Germany's low coronavirus mortality rate intrigues experts|date=22 March 2020|work=The Guardian|access-date=24 March 2020|language=en-GB|issn=0261-3077}}</ref> As of 19 March drive-in tests were offered in several large cities.<ref>{{Cite news|url=https://www.deutschlandfunk.de/covid-19-tests-auf-das-coronavirus-wann-wo-und-wie.1939.de.html?drn:news_id=1112050|title=Covid-19 \u2013 Tests auf das Coronavirus: Wann, wo und wie?|date=19 March 2020|work=Deutschlandfunk|access-date=24 March 2020|language=de-DE}}</ref>\nAs of 26 March, the total number of tests performed in Germany was unknown, because only positive results are reported. Health minister [[Jens Spahn]] estimated 200,000 tests per week.<ref name=\"sz\">{{Cite news|last=Charisius|first=Hanno|url=https://www.sueddeutsche.de/gesundheit/covid-19-coronavirus-testverfahren-1.4855487|title=Covid-19: Wie gut testet Deutschland?|date=26 March 2020|access-date=26 March 2020|language=de}}</ref> A first lab survey revealed that as of the end of March a total of at least 483,295 samples were tested and 33,491 samples (6.9%) tested positive for SARS-CoV-2.<ref name=\"rki26\" />\n\nBy the start of April, the United Kingdom was delivering around 10,000 swab tests per day. It set a target for 100,000 per day by the end of April, eventually rising to 250,000 tests per day.<ref name=\":2\" /> The British [[NHS]] has announced that it is piloting a scheme to test suspected cases at home, which removes the risk of a patient infecting others if they come to a hospital or having to disinfect an ambulance if one is used.<ref>{{cite web |title=NHS pilots home testing for coronavirus |url=https://www.mobihealthnews.com/news/europe/nhs-pilots-home-testing-coronavirus |website=MobiHealthNews |archiveurl=https://web.archive.org/web/20200225083044/https://www.mobihealthnews.com/news/europe/nhs-pilots-home-testing-coronavirus|archivedate=25 February 2020|url-status=live |date=24 February 2020}}</ref>\n\nIn [[drive-through]] testing for COVID\u201119 for suspected cases, a healthcare professional takes sample using appropriate precautions.<ref>{{cite web|url=https://www.postbulletin.com/life/health/mayo-clinic-starts-drive-thru-testing-for-covid/article_0087a856-63e3-11ea-be76-c7558f932526.html |title=Mayo Clinic starts drive-thru testing for COVID-19|last=jkiger@postbulletin.com |first=Jeff Kiger|website=PostBulletin.com|language=en|access-date=13 March 2020}}</ref><ref>{{cite web|url=https://www.theverge.com/2020/3/11/21174880/coronavirus-testing-drive-thru-colorado-connecticut-washington |title=Some states are offering drive-thru coronavirus testing|last=Hawkins|first=Andrew J.|date=11 March 2020|website=The Verge|language=en|access-date=13 March 2020}}</ref> Drive-through centers have helped [[South Korea]] do some of the fastest, most-extensive testing of any country.<ref>{{cite web|url=https://www.npr.org/sections/goatsandsoda/2020/03/13/815441078/south-koreas-drive-through-testing-for-coronavirus-is-fast-and-free?t=1584350615980 |title=South Korea's Drive-Through Testing For Coronavirus Is Fast \u2013 And Free|date=11 March 2020|website=npr |language=en|access-date=16 March 2020}}</ref> Hong Kong has set up a scheme where suspected patients can stay home, \"[the] emergency department will give a specimen tube to the patient\", they spit into it, send it back and get a test result a while after.<ref>{{cite web|url=https://www.npr.org/sections/goatsandsoda/2020/02/23/808290390/in-age-of-covid-19-hong-kong-innovates-to-test-and-quarantine-thousands|title=In Age of COVID-19, Hong Kong Innovates To Test And Quarantine Thousands|website=NPR.org|language=en}}</ref>\n\nIn Israel, researchers at [[Technion \u2013 Israel Institute of Technology|Technion]] and [[Rambam Health Care Campus|Rambam Hospital]] developed and tested a method for testing samples from 64 patients simultaneously, by [[group testing|pooling the samples]] and only testing further if the combined sample is found to be positive.<ref>{{cite news |title=Pooling method allows dozens of COVID-19 tests to run simultaneously |url=https://medicalxpress.com/news/2020-03-pooling-method-dozens-covid-simultaneously.html |accessdate=24 March 2020 |work=medicalxpress.com |language=en-us}}</ref><ref>{{cite news |title=Israeli team has coronavirus test kit to test dozens of people at once |url=https://www.jpost.com/HEALTH-SCIENCE/Acceleration-in-multiple-coronavirus-tests-at-once-by-Israel-research-team-621533 |accessdate=24 March 2020 |work=The Jerusalem Post {{!}} JPost.com}}</ref><ref>{{cite news |last1=Staff |first1=Israel21c |title=Israelis introduce method for accelerated COVID-19 testing |url=https://www.israel21c.org/israelis-introduce-method-for-accelerated-covid-19-testing/ |accessdate=24 March 2020 |work=Israel21c |date=19 March 2020}}</ref> Pool testing was then adopted in Israel, Germany, South Korea,<ref>{{cite news |title=[Coronavirus] Verified 'sample pooling' introduced to prevent herd infection in S. Korea |url=http://www.ajudaily.com/view/20200409140926759 |accessdate=19 April 2020 |work=www.ajudaily.com |date=9 April 2020 |language=en}}</ref> and [[Nebraska]],<ref>{{cite news |title=Gov. Ricketts provides update on coronavirus testing |url=https://www.3newsnow.com/news/coronavirus/live-gov-ricketts-provides-coronavirus-briefing-3-24-20 |accessdate=19 April 2020 |work=KMTV |date=24 March 2020 |language=en}}</ref> and the Indian states [[Uttar Pradesh]],<ref>{{cite news |title=Latest coronavirus update: UP to begin 'pool testing' of Covid suspects |url=https://www.freepressjournal.in/india/latest-coronavirus-update-up-to-begin-pool-testing-of-covid-suspects |accessdate=19 April 2020 |work=Free Press Journal |language=en}}</ref> [[West Bengal]],<ref>{{cite news |author=Sumati Yengkhom |title=West Bengal to start pool testing of samples in low-risk zones |url=https://timesofindia.indiatimes.com/city/kolkata/bengal-to-start-pool-testing-of-samples-in-low-risk-zones/articleshow/75227413.cms |accessdate=19 April 2020 |work=The Times of India |language=en}}</ref> [[Punjab]],<ref>{{cite news |title=Punjab launches pool testing |url=https://www.tribuneindia.com/news/punjab/punjab-launches-pool-testing-71594 |accessdate=19 April 2020}}</ref> [[Chhattisgarh]],<ref>{{cite news |title='Chhattisgarh to adopt pool sample testing': Health minister TS Singh Deo on Covid-19 |url=https://www.hindustantimes.com/india-news/chhattisgarh-to-adopt-pool-sample-testing-health-minister-ts-singh-deo-on-covid-19/story-qUnbTE2WgfhAv72aqclkXN.html |accessdate=19 April 2020 |work=Hindustan Times |date=15 April 2020 |language=en}}</ref> and [[Maharashtra]].<ref>{{cite news |title=Maharashtra to go for pool testing to defeat coronavirus |url=https://www.deccanherald.com/national/west/maharashtra-to-go-for-pool-testing-to-defeat-coronavirus-824331.html |accessdate=19 April 2020 |work=Deccan Herald |date=12 April 2020 |language=en}}</ref>\n\nIn Wuhan a makeshift 2000-sq-meter emergency detection laboratory named \"Huo-Yan\" ({{Zh|c=\u706b\u773c|s=|t=|p=}}, \"Fire Eye\") was opened on 5 February 2020 by [[BGI Group|BGI]],<ref name=\":19\">{{Cite web|url=https://www.bloomberg.com/news/articles/2020-02-04/china-will-soon-find-out-if-mass-quarantine-worked-virus-update |title=Wuhan Test Lab Opens; CDC Ships Diagnostic Kits: Virus Update|last=|first= |date=5 February 2020|website=Bloomberg |url-status=live|archive-url=|archive-date= |access-date=7 February 2020}}</ref><ref name=\":23\">{{Cite web|url=https://www.afp.com/en/news/826/china-virus-crisis-deepens-whistleblower-doctor-dies-doc-1oq8cx13 |title=China virus crisis deepens as whistleblower doctor dies|website=AFP.com|date=27 February 2012|language=en|access-date=7 February 2020}}</ref> which can process over 10,000 samples a day.<ref>{{cite news|url=http://news.sciencenet.cn/htmlnews/2020/2/435435.shtm |script-title=zh:\u65e5\u68c0\u6d4b\u91cf\u8fbe\u4e07\u4efd\u7684\"\u706b\u773c\"\u5b9e\u9a8c\u5ba4\u8fde\u591c\u8bd5\u8fd0\u884c}}</ref><ref name=\":23\" /> With the construction overseen by BGI-founder [[Wang Jian (geneticist)|Wang Jian]] and taking 5-days,<ref>{{Cite web|url=https://www.genengnews.com/insights/bgis-coronavirus-response-build-a-lab-in-wuhan-in-a-week/ |title=BGI's Coronavirus Response? Build a Lab in Wuhan|date=12 February 2020|website=GEN \u2013 Genetic Engineering and Biotechnology News|language=en-US|access-date=27 March 2020}}</ref> modelling has show cases in Hubei would have been 47% higher and the corresponding cost of the tackling the quarantine would have doubled if this testing capacity had not come into operation.{{citation needed|date=April 2020}} The Wuhan Laboratory has been promptly followed by Huo-Yan labs in [[Shenzhen]], [[Tianjin]], [[Beijing]], and [[Shanghai]], in a total of 12 cities across China. By 4 March 2020 the daily throughput totals were 50,000 tests per day.<ref>{{Cite web|url=https://www.bgi.com/global/covid-19-local-laboratory-solution/ |title=COVID-19 Local Laboratory Solution|website=BGI \u2013 Global|language=en-GB|access-date=27 March 2020}}</ref>\n\nOpen source, multiplexed designs released by Origami Assays have been released that can test as many as 1122 patient samples for COVID19 using only 93 assays.<ref>{{cite web |url= https://www.smarterbetter.design/origamiassays/default/index |title= Origami Assays  |publisher= Origami Assays |access-date=April 7, 2020|date =April 2, 2020 }}</ref>  These balanced designs can be run in small laboratories without the need for robotic liquid handlers.\n\nBy March, [[Shortages related to the 2019\u201320 coronavirus pandemic|shortages]] and insufficient amounts of [[reagent]] has become a [[Bottleneck (production)|bottleneck]] for mass testing in the EU and UK<ref>{{cite web |title=Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK \u2013seventh update |url=https://www.ecdc.europa.eu/sites/default/files/documents/RRA-seventh-update-Outbreak-of-coronavirus-disease-COVID-19.pdf |publisher=[[European Centre for Disease Prevention and Control]] |accessdate=29 March 2020 |pages=15\u201316 |date=25 March 2020 |quote=the current shortages of laboratory consumables and reagents affect diagnostic capacity and hamper the epidemic response at the national and local levels. The laboratories have experienced delayed or missing deliveries of swabbing material, plastic consumables, RNA extraction and RT-PCR reagents, and PPE. This is affecting laboratories in all EU/EEA countries. |url-status=live}}</ref> and the US.<ref>{{cite web |last1=Baird |first1=Robert P. |title=Why Widespread Coronavirus Testing Isn't Coming Anytime Soon |url=https://www.newyorker.com/news/news-desk/why-widespread-coronavirus-testing-isnt-coming-anytime-soon |website=[[The New Yorker]] |accessdate=29 March 2020 |archiveurl= https://web.archive.org/web/20200328133105/https://www.newyorker.com/news/news-desk/why-widespread-coronavirus-testing-isnt-coming-anytime-soon |archivedate=28 March 2020 |language=en |date=24 March 2020 |quote=South Dakota, said that her state\u2019s public-health laboratory\u2014the only lab doing COVID-19 testing in the state\u2014had so much trouble securing reagents that it was forced to temporarily stop testing altogether. also noted critical shortages of extraction kits, reagents, and test kits |url-status=live}}</ref><ref>{{cite web |last1=Ossola |first1=Alexandra |title=Here are the coronavirus testing materials that are in short supply in the US |url=https://qz.com/1822596/all-the-coronavirus-test-materials-in-short-supply-in-the-us/ |website=Quartz |accessdate=29 March 2020 |archiveurl= https://web.archive.org/web/20200326174135/https://qz.com/1822596/all-the-coronavirus-test-materials-in-short-supply-in-the-us/ |archivedate=26 March 2020 |language=en |date=25 March 2020 |quote=extract the virus\u2019s genetic material\u2014in this case, RNA\u2014using a set of chemicals that usually come in pre-assembled kits. \u201cThe big shortage is extraction kits\u201d There are no easy replacements here: \u201cThese reagents that are used in extraction are fairly complex chemicals. They have to be very pure, and they have to be in pure solution\u201d |url-status=live}}</ref> This has led some authors to explore sample preparation protocols that involve heating samples at {{cvt|98|C|F}} for 5 minutes to release [[RNA genome]]s for further testing.<ref name=ssi-boil>{{cite web |last1=Fomsgaard |first1=Anders |title=Statens Serum Institut (SSI) solves essential COVID-19 testing deficiency problem |url=https://en.ssi.dk/news/news/2020/03-ssi--solves-essential-covid19-testing-deficiency-problem |website=en.ssi.dk |publisher=[[Statens Serum Institut]] |archiveurl= https://web.archive.org/web/20200329085152/https://en.ssi.dk/news/news/2020/03-ssi--solves-essential-covid19-testing-deficiency-problem |archivedate=29 March 2020 |language=en |date=27 March 2020 |url-status=live |quote=several countries are in lack of the chemical reagents necessary to test their citizens for the disease. }}</ref><ref>{{cite web |title=Danish researchers behind simple&nbsp;coronavirus test method |publisher=[[The Copenhagen Post]] |url=http://cphpost.dk/?p=112522 |website=cphpost.dk |archiveurl=https://web.archive.org/web/20200328130357/http://cphpost.dk/?p=112522 |archivedate=28 March 2020 |date=28 March 2020 |url-status=live}}</ref>\n\nOn 31 March it was announced [[United Arab Emirates]] was now testing more of its population for Coronavirus per head than any other country, and was on track to scale up the level of testing to reach the bulk of the population.<ref>{{Cite news|last=Sullivan (now|first=Helen|url=https://www.theguardian.com/world/live/2020/mar/31/coronavirus-live-news-usa-confirmed-cases-double-china-update-uk-italy-spain-europe-latest-updates?page=with%3Ablock-5e8377658f087564da1e3396|title=Global confirmed virus death toll passes 40,000 \u2013 as it happened|date=31 March 2020|work=The Guardian|access-date=1 April 2020|last2=Rawlinson|first2=earlier); Kevin|language=en-GB|issn=0261-3077|last3=Gayle|first3=Damien|last4=Topping|first4=Alexandra|last5=Mohdin|first5=and Aamna|last6=Willsher|first6=Kim|last7=Wintour|first7=Patrick|last8=Wearden|first8=Graeme|last9=Greenfield|first9=Patrick}}</ref> This was through a combination of drive-through capability, and purchasing a population-scale mass-throughput laboratory from Group 42 and [[BGI Group|BGI]] (based on their \"Huo-Yan\" emergency detection laboratories in China). Constructed in 14 days, the lab is capable of conducting tens of thousands RT-PCR tests per day and is the first in the world of this scale to be operational outside of China.<ref>{{Cite web|url=https://www.gulftoday.ae/news/2020/03/31/uae-sets-up-covid-19-detection-lab-in-just-14-days|title=VIDEO: UAE sets up COVID-19 detection lab in just 14 days|last=|first=|date=31 March 2020|website=Gulf Today|url-status=live|archive-url=|archive-date=|access-date=}}</ref>\n\nOn 8 April 2020, In India, the Supreme Court of India ruled that private labs should be reimbursed at the appropriate time for COVID-19 tests <ref> [http://www.businessworld.in/article/Private-Labs-Should-Be-Reimbursed-At-Appropriate-Time-For-COVID-19-Tests-Says-AIIMS-RDA-General-Secretary/13-04-2020-188994/ Private Labs Should Be Reimbursed At Appropriate Time For COVID-19 Tests, Says AIIMS RDA General Secretary] </ref> However private labs have stated that they are unable to scale up the testing because of the price cap put on the testing and labs being forced to make advance payment to suppliers while they receive deferred payment from hospitals. <ref> [https://economictimes.indiatimes.com/news/politics-and-nation/private-laboratories-struggle-with-price-caps-on-covid-19-tests-do-only-17-tests/articleshow/75310421.cms Covid-19: Private laboratories struggle with price caps, do only 17% tests] </ref>\n\n==Production and volume==\n[[File:Lab-specimens-tested.jpg|thumb|upright=1.6|Number of tests done per day in the United States.<br />\nBlue: CDC lab<br />\nOrange: Public health lab<br />\nGray: Data incomplete due to reporting lag<br />\nNot shown: Testing at private labs; total exceeded 100,000 per day by March 27<ref>{{Cite web|url=https://arstechnica.com/tech-policy/2020/04/americas-covid-19-testing-has-stalled-and-thats-a-big-problem/|title=America's COVID-19 testing has stalled, and that's a big problem|first=Timothy B.|last=Lee|date=2 April 2020|website=Ars Technica}}</ref>]]\n\nDifferent testing recipes targeting different parts of the coronavirus genetic profile were developed in China, France, Germany, Hong Kong, Japan, the United Kingdom, and the United States. The [[World Health Organization]] adopted the German recipe for manufacturing kits sent to low-income countries without the resources to develop their own. The German recipe was published on 17 January 2020; the protocol developed by the [[United States Centers for Disease Control]] (CDC) was not available until 28 January, delaying available tests in the U.S.<ref>{{Cite web|url=https://www.politifact.com/factchecks/2020/mar/16/joe-biden/biden-falsely-says-trump-administration-rejected-w/|title=PolitiFact \u2013 Biden falsely says Trump administration rejected WHO coronavirus test kits (that were never offered)|website=@politifact}}</ref>\n\nChina<ref name=Wuhan-virus /> and the United States<ref name=Boston-virus /> had problems with the reliability of test kits early in the outbreak, and these countries and Australia<ref>{{cite web|url=https://www.theguardian.com/australia-news/2020/mar/14/coronavirus-australian-stocks-of-covid-19-testing-kits-rapidly-deteriorating-says-chief-medical-officer|title=Australian stocks of coronavirus testing kits 'rapidly deteriorating', says chief medical officer|first=Melissa|last=Davey|date=14 March 2020|via=www.theguardian.com}}</ref> were unable to supply enough kits to satisfy demand and recommendations for testing by health experts. In contrast, experts say South Korea's broad availability of testing helped reduce the spread of the novel coronavirus. Testing capacity, largely in private sector labs, was built up over several years by the South Korean government.<ref>{{cite web|url=https://www.npr.org/2020/03/12/815097813/experts-credit-south-koreas-extensive-testing-for-curbing-coronavirus-spread|title=Experts Credit South Korea's Extensive Testing For Curbing Coronavirus Spread|website=NPR.org}}</ref> On 16 March, the [[World Health Organization]] called for ramping up the testing programmes as the best way to slow the advance of COVID\u201119 pandemic.<ref>{{cite news |title='Test, Test, Test': WHO Chief's Coronavirus Message to World |url=https://www.nytimes.com/reuters/2020/03/16/world/europe/16reuters-healthcare-coronavirus-who.html |accessdate=16 March 2020 |work=The New York Times |date=16 March 2020}}</ref><ref>{{cite news |last1=Reuters |first1=Source |title='Test, test, test': WHO calls for more coronavirus testing \u2013 video |url=https://www.theguardian.com/world/video/2020/mar/16/test-test-test-who-calls-for-more-coronavirus-testing-video |accessdate=16 March 2020 |work=The Guardian |date=16 March 2020}}</ref>\n\nHigh demand for testing due to wide spread of the virus caused backlogs of hundreds of thousands of tests at private U.S. labs, and supplies of swabs and chemical reagents became strained.<ref>{{Cite web|url=https://www.npr.org/sections/health-shots/2020/04/03/826564948/coronavirus-testing-backlogs-continue-as-laboratories-struggle-to-keep-up-with-d|title=Coronavirus Testing Backlogs Continue As Laboratories Struggle To Keep Up With Demand|website=NPR.org}}</ref>\n\n==Available tests==\n===PCR based===\nWhen scientists from China first released information on the COVID\u201119 viral genome on January 11, 2020, the Malaysian Institute for Medical Research (IMR) successfully produced the \u201cprimers and probes\u201d specific to SARS-CoV-2 on the very same day. The IMR's laboratory in [[Kuala Lumpur]] had initiated early preparedness by setting up reagents to detect coronavirus using the rt-PCR method.<ref>{{Cite web|url=https://kpkesihatan.com/2020/02/13/laboratory-readiness-for-detecting-the-2019-novel-coronavirus-2019-ncov-infection-in-malaysia/|title=Laboratory Readiness for Detecting the 2019 novel coronavirus (2019-nCoV) infection in Malaysia|last=|first=|date=9 February 2020|website=Director-General of Health, Malaysia|url-status=live|archive-url=|archive-date=|access-date=}}</ref> The WHO reagent sequence (primers and probes) released several days later was very similar to that produced in the IMR's laboratory, which was used to  diagnose Malaysia's first COVID\u201119 patient on January 24, 2020.<ref>{{Cite web|url=https://www.thestar.com.my/opinion/letters/2020/03/26/malaysia-must-ramp-up-testing?itm_source=parsely-api|title=Malaysia must ramp up testing|last=|first=|date=26 March 2020|website=The Star Malaysia|url-status=live|archive-url=|archive-date=|access-date=}}</ref>\n\n[[Public Health England]] developed a test by 10 January,<ref>{{Cite news|last=|first=|url=https://uk.reuters.com/article/uk-health-coronavirus-britain-modelling-idUKKCN21R2UF|title=UK defends coronavirus response after Reuters investigation|date=2020-04-09|work=Reuters|access-date=2020-04-12|url-status=live|language=en|quote=After developing a test for the new virus by Jan. 10}}</ref> using real-time RT-PCR (RdRp gene) assay based on oral swabs.<ref>{{Cite web|url=https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/guidance-and-sop-covid-19-virus-testing-in-nhs-laboratories-v1.pdf|title=COVID-19 virus testing in NHS laboratories|last=|first=|date=16 March 2020|website=|publisher=NHS England and NHS Improvement|url-status=live|archive-url=|archive-date=|access-date=}}</ref> The test detected the presence of any type of coronavirus including specifically identifying SARS-CoV-2. It was rolled out to twelve laboratories across the United Kingdom on February 10.<ref>{{Cite web|url=https://www.gov.uk/government/news/phe-novel-coronavirus-diagnostic-test-rolled-out-across-uk|title=PHE novel coronavirus diagnostic test rolled out across UK|website=GOV.UK|language=en|access-date=30 March 2020|postscript=none}}; {{Cite news|url=https://www.bbc.com/news/uk-51221915|title='Increased likelihood' of China virus reaching UK|date=23 January 2020|work=BBC News|access-date=30 March 2020|language=en-GB|postscript=none}}; {{Cite web|url=https://www.pharmaceutical-journal.com/news-and-analysis/news/phe-tells-patients-with-suspected-coronavirus-to-call-gp-or-nhs-111/20207619.article|title=PHE tells patients with suspected coronavirus to call GP or NHS 111|date=27 January 2020|publisher=The Pharmaceutical Journal|language=en|access-date=30 March 2020}}</ref> Another early PCR test was developed by [[Charit\u00e9]] in Berlin, working with academic collaborators in Europe and Hong Kong, and published on 23 January. It used rtRT-PCR, and formed the basis of 250,000 kits for distribution by the [[World Health Organization]] (WHO).<ref name=sheridan>{{cite journal |last1=Sheridan |first1=Cormac |title=Coronavirus and the race to distribute reliable diagnostics |url=https://www.nature.com/articles/d41587-020-00002-2 |journal=Nature Biotechnology |language=en |doi=10.1038/d41587-020-00002-2 |date=19 February 2020|volume=38 |issue=4 |pages=382\u2013384 |pmid=32265548 |doi-access=free }}</ref> The South Korean company Kogenebiotech developed a clinical grade, PCR-based SARS-CoV-2 detection kit (''PowerChek Coronavirus'') on 28 January 2020.<ref>{{cite web|url=http://www.kogene.co.kr/eng/index.php |title=KogeneBiotech |publisher=Kogene.co.kr |date= |accessdate=16 March 2020}}</ref><ref>{{cite news |last1=Jeong |first1=Sei-im |title=Korea approves 2 more COVID-19 detection kits for urgent use \u2013 Korea Biomedical Review |url=http://www.koreabiomed.com/news/articleView.html?idxno=7561 |accessdate=12 March 2020 |work=koreabiomed.com |date=28 February 2020 |language=ko}}</ref> It looks for the \"E\" gene shared by all [[beta coronavirus]]es, and the RdRp gene specific to SARS-CoV-2.<ref>{{Cite web|url=http://www.kogene.co.kr/eng/about_us/news/listbody.php?h_gcode=board&h_code=7&po_no=288|title=ABOUT US &#124; NEWS|website=kogene.co.kr}}</ref>\n\nIn China, [[BGI Group]] was one of the first companies to receive emergency use approval from China's [[National Medical Products Administration]] for a PCR-based SARS-CoV-2 detection kit.<ref>{{cite web|url=https://www.genomeweb.com/regulatory-news-fda-approvals/bgi-sequencer-coronavirus-molecular-assays-granted-emergency-use|title=BGI Sequencer, Coronavirus Molecular Assays Granted Emergency Use Approval in China|website=GenomeWeb|access-date=9 March 2020}}</ref>\n\nIn the United States, the CDC distributed its SARS-CoV-2 Real Time PCR Diagnostic Panel to public health labs through the International Reagent Resource.<ref>{{cite web|url=https://www.internationalreagentresource.org/|title=International Reagent Resource |website=internationalreagentresource.org}}</ref> One of three genetic tests in older versions of the test kits caused inconclusive results due to faulty reagents, and a bottleneck of testing at the CDC in Atlanta; this resulted in an average of fewer than 100 samples a day being successfully processed throughout the whole of February 2020. Tests using two components were not determined to be reliable until 28 February 2020, and it was not until then that state and local laboratories were permitted to begin testing.<ref>[https://www.cdc.gov/media/releases/2020/t0228-COVID-19-update.html Transcript for the CDC Telebriefing Update on COVID-19], 28 February 2020</ref> The test was approved by the FDA under an EUA.{{citation needed|date=March 2020}}\n\nUS commercial labs began testing in early March 2020. As of 5 March 2020 [[LabCorp]] announced nationwide availability of COVID\u201119 testing based on RT-PCR.<ref>{{Cite web|url=https://ir.labcorp.com/news-releases/news-release-details/labcorp-launches-test-coronavirus-disease-2019-covid-19|title=LabCorp Launches Test for Coronavirus Disease 2019 (COVID-19)|website=Laboratory Corporation of America Holdings}}</ref> [[Quest Diagnostics]] similarly made nationwide COVID\u201119 testing available as of 9 March 2020.<ref>{{cite web|url=https://www.questdiagnostics.com/home/Covid-19/|title=Covid19 : COVID-19|website=questdiagnostics.com}}</ref>\n\nIn Russia, the COVID\u201119 test was developed and produced by the [[State Research Center of Virology and Biotechnology VECTOR]]. On 11 February 2020 the test was registered by the [[Federal Service for Surveillance in Healthcare]].<ref>{{Cite web|url=http://www.interfax-russia.ru/kaleidoscope.asp?id=1104973|title=\u0412 \u0420\u043e\u0441\u0441\u0438\u0438 \u0437\u0430\u0440\u0435\u0433\u0438\u0441\u0442\u0440\u0438\u0440\u043e\u0432\u0430\u043d\u0430 \u043e\u0442\u0435\u0447\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u0430\u044f \u0442\u0435\u0441\u0442-\u0441\u0438\u0441\u0442\u0435\u043c\u0430 \u0434\u043b\u044f \u043e\u043f\u0440\u0435\u0434\u0435\u043b\u0435\u043d\u0438\u044f \u043a\u043e\u0440\u043e\u043d\u0430\u0432\u0438\u0440\u0443\u0441\u0430|date=14 February 2020|website=Interfax-Russia.ru}}</ref>\n\nOn 12 March 2020, [[Mayo Clinic]] was reported to have developed a test to detect COVID\u201119 infection.<ref>{{cite web|url=https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-develops-test-to-detect-covid-19-infection/|title=Mayo Clinic develops test to detect COVID-19 infection|last=Plumbo|first=Ginger|website=[[Mayo Clinic]]|language=en-US|access-date=13 March 2020}}</ref>\n\nOn 19 March 2020, the FDA issued EUA to [[Abbott Laboratories]]<ref>{{cite web |url=https://www.molecular.abbott/us/en/products/instrumentation/m2000-realtime-system |title=M2000 Realtime System |publisher= Abbott Labs |access-date=April 13, 2020}}</ref> for a test on Abbott's m2000 system; the FDA had previously issued similar authorization to [[Hologic]],<ref>{{cite web |url=https://investors.hologic.com/press-releases/press-release-details/2020/Hologics-Molecular-Test-for-the-Novel-Coronavirus-SARS-CoV-2-Receives-FDA-Emergency-Use-Authorization/default.aspx |title=Hologic's Molecular Test for the Novel Coronavirus, SARS-CoV-2, Receives FDA Emergency Use Authorization |publisher=Hologic |access-date=April 13, 2020|date = March 16, 2020}}</ref> [[LabCorp]],<ref>{{cite web |url=https://ir.labcorp.com/news-releases/news-release-details/labcorp-launches-test-coronavirus-disease-2019-covid-19 |title= LabCorp Launches Test for Coronavirus Disease 2019 (COVID-19) |publisher=LabCorp |access-date=April 13, 2020}}</ref> and [[Thermo Fisher Scientific]].<ref>{{cite web |url=https://www.thermofisher.com/us/en/home/clinical/clinical-genomics/pathogen-detection-solutions/coronavirus-2019-ncov/genetic-analysis/taqpath-rt-pcr-covid-19-kit.html |title= TaqPath COVID-19 Multiplex Diagnostic Solution |publisher=ThermoFisher |access-date=April 13, 2020}}</ref><ref>{{cite web|url=https://www.ibtimes.com/fda-approves-abbott-laboratories-coronavirus-test-company-ship-150000-kits-2942677 |title=FDA Approves Abbott Laboratories Coronavirus Test, Company To Ship 150,000 Kits |date=19 March 2020 |website=IBTimes.com |archive-url=https://web.archive.org/web/20200320210743/https://www.ibtimes.com/fda-approves-abbott-laboratories-coronavirus-test-company-ship-150000-kits-2942677 |archive-date=20 March 2020 |url-status=live}}</ref> On 21 March 2020, [[Cepheid Inc|Cepheid]] similarly received an EUA from the FDA for a test that takes about 45 minutes on its GeneXpert system; the same system that runs the [[GeneXpert MTB/RIF]].<ref>{{cite web| url=https://www.eastbaytimes.com/2020/03/21/coronavirus-test-45-minute-cepheid-sunnyvale-covid-19-test/ |title=Sunnyvale company wins FDA approval for first rapid coronavirus test with 45-minute detection time |website=EastBayTimes.com |date=21 March 2020 |archive-url=https://archive.is/iz2H7# |archive-date=22 March 2020 |url-status=live}}</ref><ref>{{Cite web|url=https://www.cepheid.com/coronavirus|title=Xpert\u00ae Xpress SARS-CoV-2 has received FDA Emergency Use Authorization|website=www.cepheid.com|language=en-US|access-date=2020-04-13}}</ref>\n\nOn 13 April, [[Health Canada]] approved a test from [[Spartan Bioscience]]. Institutions may \"test patients\" with a handheld [[DNA analyzer]] \"and receive results without having to send samples away to a [central] lab.\"<ref name=\"carly\">{{cite news |title=Health Canada approves new rapid COVID-testing kits |url=https://www.theglobeandmail.com/canada/article-health-canada-approves-new-rapid-covid-testing-kits/ |publisher=The Globe and Mail Inc |date=13 April 2020}}</ref><ref>{{cite web |url=https://www.spartanbio.com/ |title=The power of DNA testing for everyone |publisher=Spartan Bioscience |access-date=April 14, 2020}}</ref>\n\n===Isothermal nucleic amplification===\n[[File:President Trump Delivers Remarks During a Coronavirus Update Briefing (49720569077).jpg|thumb|US President [[Donald Trump]] displays a COVID\u201119 testing kit from [[Abbott Laboratories]] in March 2020]]\nThe FDA has approved a test by [[Abbott Laboratories]] that uses isothermal nucleic acid amplification technology instead of PCR.<ref name=\"Letter from FDA\"/> Since this does not require a series of alternating temperature cycles (like [[PCR]] tests typically do) this method can deliver positive results in as little as five minutes and negative results in 13 minutes.  There are currently about 18,000 of these machines in the U.S. and Abbott expects to ramp up manufacturing to deliver 50,000 tests per day.<ref>{{cite web |url=https://www.usatoday.com/story/news/health/2020/03/28/coronavirus-fda-authorizes-abbott-labs-fast-portable-covid-test/2932766001/ |title='A game changer': FDA authorizes Abbott Labs' portable, 5-minute coronavirus test the size of a toaster |publisher=USA Today |access-date=April 20, 2020|date =March 28, 2020 }}</ref>\n\n===Accuracy===\nIn March 2020 China<ref name=Wuhan-virus>[https://www.bloomberg.com/news/articles/2020-03-12/heartbreak-in-the-streets-of-wuhan Heartbreak in the Streets of Wuhan]</ref> reported problems with accuracy in their test kits.\n\nIn the United States, the test kits developed by the CDC had \"flaws;\" the government then removed the bureaucratic barriers that had prevented private testing.<ref name=Boston-virus>{{cite web|url=https://www.bostonglobe.com/2020/03/14/metro/baker-sets-up-virus-command-center/|title=State figures on testing raise questions about efforts to contain outbreak |website=The BostonGlobe.com |quote=flaws with the testing kits first distributed by the federal government and bureaucratic hurdles that held up testing by private labs at hospitals, universities and testing chains}}</ref>\n\nSpain purchased test kits from Chinese firm  Shenzhen Bioeasy Biotechnology Co Ltd, but found that results were inaccurate. The firm explained that the incorrect results may be a result of a failure to collect samples or use the kits correctly. The Spanish ministry said it will withdraw the kits that returned incorrect results, and would replace them with a different testing kit provided by Shenzhen Bioeasy.<ref>{{Cite web|url=https://www.reuters.com/article/us-health-coronavirus-shenzhen-bioeasy-s-idUSKBN21E161|title=Chinese firm to replace exported coronavirus test kits deemed defective by Spain|date=27 March 2020|via=www.reuters.com}}</ref>\n\n80% of test kits the Czech Republic purchased from China gave wrong results.<ref>{{Cite web|url=https://www.praguemorning.cz/80-of-rapid-covid-19-tests-the-czech-republic-bought-from-china-are-wrong/|title=80% of Rapid COVID-19 Tests the Czech Republic Bought From China are Wrong|first=Prague|last=Morning|date=26 March 2020}}</ref><ref>{{cite news |last1=VOJT\u011aCH BLA\u017dEK |title=\u00da\u0159ad dop\u0159edu psal, kdy mohou rychlotesty selhat. I tak je st\u00e1t nasadil |url=https://www.seznamzpravy.cz/clanek/rychlotesty-neodhali-cerstve-nakazene-pacienty-varoval-zdravotni-ustav-95174 |accessdate=7 April 2020 |work=Zeznam Zpr\u00e1vy |date=23 March 2020 |language=Czech |quote=Indeed, the rapid tests that arrived from China a few days ago do not really reliably detect the infection at an early stage}}</ref>\n\nSlovakia purchased 1.2&nbsp;million test kits from China which were found to be inaccurate. Prime Minister Matovi\u010d suggested these be dumped into the [[Danube]].<ref>{{Cite web|url=https://fortune.com/2020/04/01/europe-china-coronavirus-testing-help-regret/|title=Europe turned to China for coronavirus testing help. Why some are now regretting it|website=Fortune}}</ref>\n\nAte\u015f Kara of the Turkish Health Ministry said the test kits Turkey purchased from China had a \"high error rate\" and did not \"put them into use.\"<ref>{{Cite web|url=https://www.duvarenglish.com/health-2/coronavirus/2020/03/27/coronavirus-test-kits-purchased-from-china-are-unreliable-says-science-committee-member/|title=Coronavirus test kits purchased from China are unreliable, says Science Committee member|website=www.duvarenglish.com}}</ref><ref>{{Cite web|url=http://www.middleeasteye.net/news/coronavirus-turkey-faulty-chinese-kits-not-use|title=Coronavirus: Turkey rejects Chinese testing kits over inaccurate results|website=Middle East Eye}}</ref>\n\nThe UK purchased 3.5&nbsp;million test kits from China but in early April 2020 announced these were not usable.<ref>{{Cite web|url=https://www.thetimes.co.uk/article/britain-has-millions-of-coronavirus-antibody-tests-but-they-don-t-work-j7kb55g89|title=Britain has millions of coronavirus antibody tests, but they don't work|first=Chris Smyth, Whitehall Editor &#124; Dominic Kennedy, Investigations Editor &#124; Billy Kenber, Investigations|last=Reporter|via=www.thetimes.co.uk}}</ref><ref>{{Cite web|url=https://www.independent.co.uk/news/uk/home-news/coronavirus-test-antibody-kit-uk-china-nhs-matt-hancock-a9449816.html|title=Government's testing chief admits none of 3.5m coronavirus antibody kits work sufficiently|date=6 April 2020|website=The Independent}}</ref>\n\nOn April 21, 2020 [[Indian Council of Medical Research]], India has advised states to stop using the rapid antibody test kits purchased from China after receiving complaints from one state. Rajasthan health minister Raghu Sharma on Apr 21, 2020 said the kits gave only 5.4 percent accurate results against the expectation of 90 percent accuracy.<ref>{{Cite web|url=https://www.telegraphindia.com/india/icmr-asks-states-not-to-use-rapid-test-kits-for-two-days/cid/1766876|title=ICMR asks states not to use rapid test kits for two days|date=21 April 2020|website=The Telegraph}}</ref>\n\n===Confirmatory testing===\nWHO recommends that countries that do not have testing capacity and national laboratories with limited experience on COVID\u201119 send their first five positives and the first ten negative COVID\u201119 samples to one of the 16 WHO reference laboratories for confirmatory testing.<ref>{{cite web |title=National laboratories |url=https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance |website=who.int |language=en}}</ref><ref>{{Cite web|url=https://www.gov.uk/government/news/phe-novel-coronavirus-diagnostic-test-rolled-out-across-uk|title=PHE novel coronavirus diagnostic test rolled out across UK|last=|first=|date=|website=GOV.UK|language=en|url-status=live|archive-url=|archive-date=|access-date=2020-04-12|quote=In addition to processing samples from suspected cases in this country, PHE is now working as a reference laboratory for WHO, testing samples from countries that do not have assured testing capabilities.}}</ref> Out of the 16 reference laboratories, 7 are in Asia, 5 in Europe, 2 in Africa, 1 in North America and 1 in Australia.<ref>{{cite web |title=Specimen referral for COVID-19 \u2013 operational details of WHO reference laboratories providing confirmatory testing for COVID-19 |url=https://www.who.int/docs/default-source/coronaviruse/who-reference-laboratories-providing-confirmatory-testing-for-covid-19.pdf?sfvrsn=a03a01e6_2 |website=World Health Organization |accessdate=29 March 2020}}</ref>\n\n===WHO Emergency Use Listing===\n{| class=\"wikitable\" style = \"float: right; margin-left:15px\"\n|+Diagnostic tests accepted by the WHO for procurement\n|-\n! Date listed !! Product name !! Manufacturer\n|-\n| 03/4/2020 || Cobas SARS-CoV-2 qualitative assay for use on the cobas 6800/8800 Systems ||[[Roche Diagnostics|Roche Molecular Systems]]\n|-\n| 07/4/2020 || Coronavirus (COVID-19) genesig rtPCR assay ||[[Primerdesign]]\n|-\n| 09/4/2020 || Abbott Realtime SARS-CoV-2 ||[[Abbott Laboratories|Abbott Molecular]]\n|}\nAs of 7 April 2020, the WHO had accepted two diagnostic tests for procurement under the Emergency Use Listing procedure (EUL) for use during the COVID\u201119 pandemic, in order to increase access to quality-assured, accurate tests for the disease.<ref>{{cite web |title=WHO lists two COVID-19 tests for emergency use |url=https://www.who.int/news-room/detail/07-04-2020-who-lists-two-covid-19-tests-for-emergency-use |website=[[World Health Organization]] |accessdate=10 April 2020}}</ref> Both [[in vitro]] diagnostics, the tests are genesig Real-Time PCR Coronavirus (COVID\u201119) manufactured by [[Primerdesign]], and cobas SARS-CoV-2 Qualitative assay for use on the cobas\u00ae 6800/8800 Systems by [[Roche Diagnostics|Roche Molecular Systems]]. Approval means that these tests can also be supplied by the [[United Nations]] and other procurement agencies supporting the COVID\u201119 response.\n\n==Clinical effectiveness==\nTesting, followed with quarantine of those who tested positive and tracing of those with whom the SARS-CoV-2 positive people had had contact, resulted in positive outcomes.{{clarify|reason=Positive in the sense of epidemic containment being a \"positive\" social goal? Or a greater number of SARS-CoV-2 positive detections?|date=April 2020}}.{{citation needed|date=April 2020}}\n\n===Italy===\nResearchers working in the Italian town of [[V\u00f2]], the site of the first COVID\u201119 death in Italy, conducted two rounds of testing on the entire population of about 3,400 people, about ten days apart. About half the people testing positive had no symptoms, and all discovered cases were quarantined. With travel to the commune restricted, this eliminated new infections completely.<ref>{{Cite web|url=https://nationalpost.com/news/world/how-an-experiment-helped-one-italian-town-find-submerged-infections-cut-new-covid-19-cases-to-zero|title=How an experiment helped one Italian town find 'submerged infections,' cut new COVID-19 cases to zero &#124; National Post|date=19 March 2020}}</ref>\n\n===Singapore===\nWith aggressive contact tracing, inbound travel restrictions, testing, and quarantining, the [[2020 coronavirus pandemic in Singapore]] has proceeded much more slowly than in other developed countries {{Dubious|date=April 2020}}, but without extreme restrictions like forced closure of restaurants and retail establishments.  Many events have been cancelled, and Singapore did start advising residents to stay at home on 28 March, but schools reopened on time after holiday break on 23 March.<ref>{{Cite web|url=https://www.msn.com/en-sg/news/singapore/covid-19-outbreak-petition-to-close-schools-in-singapore-garners-7700-signatures-to-date/ar-BB11C87Z?li=BBr8YXK|title=COVID-19 outbreak: Petition to close schools in Singapore garners 7,700 signatures to date|website=msn.com}}</ref>\n\n===Others===\nSeveral other countries, such as Iceland<ref>{{Cite web|url=https://nordiclifescience.org/covid-19-first-results-of-the-voluntary-screening-in-iceland/|title=COVID-19: First results of the voluntary screening in Iceland|date=2020-03-27|website=Nordic Life Science \u2013 the leading Nordic life science news service|language=en-US|access-date=2020-04-05}}</ref> and South Korea,<ref>{{Cite web|url=https://www.sciencemag.org/news/2020/03/coronavirus-cases-have-dropped-sharply-south-korea-whats-secret-its-success|title=Coronavirus cases have dropped sharply in South Korea. What's the secret to its success?|last=NormileMar. 17|first=Dennis|last2=2020|date=2020-03-17|website=Science {{!}} AAAS|language=en|access-date=2020-04-05|last3=Am|first3=8:00}}</ref> have also managed the pandemic with aggressive contact tracing, inbound travel restrictions, testing, and quarantining, but with less aggressive lock-downs. A statistical study has found that countries that have tested more, relative to the number of deaths, have much lower [[case fatality rate]]s, probably because these countries are better able to detect those with only mild or no symptoms.<ref name=\":1\" />\n\n==Research and development==\nA test which uses [[monoclonal antibody|monoclonal antibodies]] which bind to the [[nucleocapsid protein]] (N protein) of the SARS-CoV-2 is being developed in Taiwan, with the hope that it can provide results in 15 to 20 minutes just like a [[rapid influenza test]].<ref>{{cite news |title=\u4e2d\u592e\u7814\u7a76\u9662\u7db2\u7ad9 |url=https://www.sinica.edu.tw/en/news/6505 |accessdate=12 March 2020 |work=sinica.edu.tw |publisher=Sinca}}</ref> The World Health Organization raised concerns on April 8 that these tests need to be validated for the disease and are in a research stage only.<ref>{{cite web |title=Advice on the use of point-of-care immunodiagnostic tests for COVID-19 |url=https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19 |website=who.int |accessdate=11 April 2020 |language=en}}</ref> The United States [[Food and Drug Administration]] approved an antibody test on April 2,<ref>Romano, Andrew. (7 April 2020). \n \"Fauci once dismissed concerns about 'silent carriers' of coronavirus. Not anymore.\" [https://news.yahoo.com/fauci-once-dismissed-concerns-about-silent-carriers-of-coronavirus-not-anymore-161718057.html Yahoo News] Retrieved 17 April 2020.</ref> but some researchers warn that such tests should not drive public health decisions unless the percentage of COVID\u201119 survivors who are producing neutralizing antibodies is also known.<ref name=SA_immun>McKenna, Stacey. (10 April 2020). \"What Immunity to COVID-19 Really Means\". [https://www.scientificamerican.com/article/what-immunity-to-covid-19-really-means/ Scientific American website] Retrieved 17 April 2020.</ref>\n\n==Virus testing statistics by country==\nThe figures are influenced by the country's testing policy. In countries with similar spread of infection, a country that only tests people admitted to hospitals will have lower \"Positive / million people\" and higher \"% (Percentage of positive tests)\" figures than a country that tests all citizens whether or not they are showing symptoms.<ref>{{cite web |url=https://www.researchgate.net/publication/340539075 |title=Sampling Bias: Explaining Wide Variations in COVID-19 Case Fatality Rates |publisher=ResearchGate |access-date=April 17, 2020|date=April 1, 2020 }}</ref>\n\n{{COVID-19 testing by country|state=expanded}}\n\n==Virus testing statistics by country subdivision==\n{{COVID-19 testing by country subdivision|state=expanded}}\n\n==References==\n{{reflist}}\n\n==External links==\n{{Commons category}}\n* [https://ourworldindata.org/covid-testing ''Data on COVID-19 testing''] at [[Our World in Data]] (March 31, 2020)\n* [https://www.c-span.org/video/?470277-1/federal-health-officials-testify-coronavirus-outbreak-response&start=4478 ''COVID-19 Testing (at least) \u2013 now Free for all?'' (CDC; US Congress; CSPAN video/6:00; March 12, 2020)]\n* [https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.3.2000045 Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR]; [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988269/ NCBI-PMC], [https://dx.doi.org/10.2807%2F1560-7917.ES.2020.25.3.2000045 DOI] (January 23, 2020)\n\n{{2019\u201320 coronavirus pandemic}}\n\n[[Category:Infectious disease blood tests]]\n[[Category:COVID-19|Testing]]\n[[Category:Medical responses to the 2019\u201320 coronavirus pandemic]]\n", "name_user": "SpicyMilkBoy", "label": "safe", "comment": "\u2192\u200eSerology:fx dab", "url_page": "//en.wikipedia.org/wiki/COVID-19_testing"}
